[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5767
1. Vincent-Salomon A, Macgrogan G, Charaffe-Jauffret E, Jacquemier J, Arnould L: [Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas]. Bull Cancer; 2010 Mar;97(3):357-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas].
  • [Transliterated title] Identification en pratique clinique des carcinomes basal-like du sein : des carcinomes "triple zéro/BRCA1-like".
  • Basal-like carcinomas represent 10 to 15% of invasive breast carcinomas and have been identified from gene expression studies.
  • They share a high degree of similarity at the morphological, phenotypical and molecular level with BRCA1 tumors that justify the proposal of a different name such as "triple zero/BRCA1 like" carcinomas for sporadic basal-like carcinomas.
  • Indeed, the current "basal-like" name could suggest a myoepithelial cellular origin of such lesions.
  • Furthermore, tumors with such a basal-like immunophenotype constitute a heterogeneous group of tumors encompassing good prognosis tumors such as adenoid cystic and juvenile secretory carcinomas.
  • There is an urgent need for more specific therapies for basal-like/triple zero/BRCA1-like tumors.
  • Indeed, recent clinical trials with PARP inhibitors for basal-like/BRCA1 like tumors should improve the prognosis of these patients and are a direct benefit of a better understanding of the molecular biology of these tumors.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Basal Cell / genetics. Gene Expression Profiling / methods. Genes, BRCA1
  • [MeSH-minor] BRCA1 Protein / genetics. BRCA1 Protein / metabolism. Biomarkers, Tumor. Female. Gene Silencing. Genes, p53 / genetics. Humans. Mutation / genetics. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Phenotype. Prognosis. Terminology as Topic


2. Mancuso M, Leonardi S, Tanori M, Pasquali E, Pierdomenico M, Rebessi S, Di Majo V, Covelli V, Pazzaglia S, Saran A: Hair cycle-dependent basal cell carcinoma tumorigenesis in Ptc1neo67/+ mice exposed to radiation. Cancer Res; 2006 Jul 1;66(13):6606-14
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hair cycle-dependent basal cell carcinoma tumorigenesis in Ptc1neo67/+ mice exposed to radiation.
  • We examined the effects of hair cycle phase on basal cell carcinoma (BCC) tumorigenesis induced by radiation in mice lacking one Patched allele (Ptc1(neo67/+)).
  • Our results show that Ptc1(neo67/+) mouse skin irradiated in early anagen is highly susceptible to tumor induction, as a 3.2-fold incidence of visible BCC-like tumors was observed in anagen-irradiated compared with telogen-irradiated mice.
  • In fact, in addition to typical BCC-like tumors, we observed development of a distinct basal cell tumor subtype characterized by anti-cytokeratin 14 and anti-smooth muscle actin reactivity.
  • In contrast, there are strong indications for the derivation of typical, smooth muscle actin-negative BCC-like tumors from cell progenitors of interfollicular epidermis.
  • These results underscore the role of follicular bulge stem cells and their progeny with high self-renewal capacity in the formation of basal cell tumors and contribute to clarify the relationship between target cell and tumor phenotype in BCC tumorigenesis induced by radiation.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Hair Follicle / radiation effects. Neoplasms, Radiation-Induced / etiology. Receptors, Cell Surface / genetics. Skin Neoplasms / etiology
  • [MeSH-minor] Allelic Imbalance. Animals. Cell Lineage. Female. Kruppel-Like Transcription Factors / biosynthesis. Kruppel-Like Transcription Factors / genetics. Loss of Heterozygosity. Male. Mice. Skin / radiation effects. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818633.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gli protein, mouse; 0 / Gli2 protein; 0 / Kruppel-Like Transcription Factors; 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


3. Karthiga KS, Sivapatha Sundharam B, Manikandan R: Nevoid basal cell carcinoma syndrome. Indian J Dent Res; 2006 Jan-Mar;17(1):50-3
Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevoid basal cell carcinoma syndrome.
  • But it was in 1960, Gorlin-Goltz established the association of basal cell epithelioma, jaw cyst and bifid ribs, a combination which is now frequently known as Gorlin-Goltz syndrome as well as Nevoid Basal Cell Carcinoma Syndrome (NBCCS).
  • [MeSH-major] Basal Cell Nevus Syndrome / diagnosis. Maxillary Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16900896.001).
  • [ISSN] 0970-9290
  • [Journal-full-title] Indian journal of dental research : official publication of Indian Society for Dental Research
  • [ISO-abbreviation] Indian J Dent Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


Advertisement
4. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med; 2009 Sep 17;361(12):1164-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
  • BACKGROUND: Mutations in hedgehog pathway genes, primarily genes encoding patched homologue 1 (PTCH1) and smoothened homologue (SMO), occur in basal-cell carcinoma.
  • In a phase 1 clinical trial, we assessed the safety and pharmacokinetics of GDC-0449, a small-molecule inhibitor of SMO, and responses of metastatic or locally advanced basal-cell carcinoma to the drug.
  • METHODS: We selected 33 patients with metastatic or locally advanced basal-cell carcinoma to receive oral GDC-0449 at one of three doses; 17 patients received 150 mg per day, 15 patients received 270 mg per day, and 1 patient received 540 mg per day.
  • We assessed tumor responses with the use of Response Evaluation Criteria in Solid Tumors (RECIST), physical examination, or both.
  • The other 15 patients had either stable disease (11 patients) or progressive disease (4 patients).
  • CONCLUSIONS: GDC-0449, an orally active small molecule that targets the hedgehog pathway, appears to have antitumor activity in locally advanced or metastatic basal-cell carcinoma. (ClinicalTrials.gov number, NCT00607724. )
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Benzimidazoles / administration & dosage. Carcinoma, Basal Cell / drug therapy. Hedgehog Proteins / antagonists & inhibitors. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anilides. Dose-Response Relationship, Drug. Female. Gene Expression. Humans. Male. Middle Aged. Mutation. Polymerase Chain Reaction. Pyridines. RNA, Messenger / metabolism. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Sequence Analysis, DNA. Signal Transduction / drug effects. Transcription Factors / genetics. Transcription Factors / metabolism


5. Lortscher DN, Sengelmann RD, Allen SB: Acrochordon-like basal cell carcinomas in patients with basal cell nevus syndrome. Dermatol Online J; 2007;13(2):21
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acrochordon-like basal cell carcinomas in patients with basal cell nevus syndrome.
  • Basal cell nevus syndrome is an autosomal dominant disorder characterized by multiple basal cell carcinomas, along with numerous other documented clinical features.
  • Acrochordons (or skin tags) are common benign neoplasms that are appropriately left untreated in most patients.
  • Our findings support the biopsy of acrochordon-like growths in patients with basal cell nevus syndrome to rule out basal cell carcinoma.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Carcinoma, Basal Cell / pathology. Cell Transformation, Neoplastic / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498440.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Akinyemi E, Mai L, Matin A, Maini A: Diffuse large B-cell lymphoma mimicking advanced basal cell carcinoma. J Natl Med Assoc; 2007 Aug;99(8):948-50
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma mimicking advanced basal cell carcinoma.
  • Primary cutaneous B-cell lymphomas (PCBCLs) are made up of a heterogenous group of B-cell lymphoproliferative diseases confined to the skin at the time of diagnosis with no evidence of extracutaneous involvement.
  • We report a case of diffuse large B-cell lymphoma (DLBCL) in a 52-year-old woman presenting as a fungating skin ulcer mimicking advanced basal cell carcinoma.
  • Clinical findings, diagnostic evaluations and treatment outcomes of PCBCLs are discussed with emphasis on comparison of European Organization for Research and Treatment of Cancer (EORTC) and the World Health Organization (WHO) Classification of Neoplasms of the Hematopoietic and Lymphoid Tissue classification systems.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Basal Cell. Combined Modality Therapy. Cyclophosphamide. Doxorubicin. Female. Humans. Middle Aged. Prednisolone. Rituximab. Treatment Outcome. Vincristine

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 2002 Feb;34(1):36-45 [11902444.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):144-7 [11841383.001]
  • [Cites] Australas J Dermatol. 2003 May;44(2):110-5 [12752183.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1183-91 [14674895.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):385-9 [8407414.001]
  • [Cites] J Am Acad Dermatol. 1994 Jul;31(1):54-60 [8021372.001]
  • [Cites] Blood. 1997 Jul 1;90(1):354-71 [9207472.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2080-5 [9626207.001]
  • [Cites] Am J Dermatopathol. 1999 Jun;21(3):265-73 [10380050.001]
  • [Cites] Br J Dermatol. 2005 Mar;152(3):541-4 [15787825.001]
  • [Cites] Radiother Oncol. 1999 Jul;52(1):15-8 [10577681.001]
  • [Cites] Blood. 2000 May 15;95(10):3052-6 [10807768.001]
  • [Cites] Br J Dermatol. 2000 May;142(5):913-23 [10809848.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1835-44 [11042581.001]
  • [Cites] Pathol Int. 2000 Dec;50(12):960-6 [11123762.001]
  • [Cites] Br J Dermatol. 2001 Jun;144(6):1239-43 [11422050.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):647-55 [11821444.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):574-80 [11939732.001]
  • (PMID = 17722675.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Other-IDs] NLM/ PMC2574298
  •  go-up   go-down


7. Epstein EH: Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer; 2008 Oct;8(10):743-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinomas: attack of the hedgehog.
  • Basal cell carcinomas (BCCs) were essentially a molecular 'black box' until some 12 years ago, when identification of a genetic flaw in a rare subset of patients who have a great propensity to develop BCCs pointed to aberrant Hedgehog signalling as the pivotal defect leading to formation of these tumours.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813320.001).
  • [ISSN] 1474-1768
  • [Journal-full-title] Nature reviews. Cancer
  • [ISO-abbreviation] Nat. Rev. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109584-06; United States / NCI NIH HHS / CA / R01 CA115992; United States / NCI NIH HHS / CA / R01 CA109584; United States / NCI NIH HHS / CA / CA115992; United States / NIAMS NIH HHS / AR / AR050440; United States / NIAMS NIH HHS / AR / P01 AR050440
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hedgehog Proteins; 0 / Receptors, Cell Surface; 0 / patched receptors
  • [Number-of-references] 199
  • [Other-IDs] NLM/ NIHMS354845; NLM/ PMC4457317
  •  go-up   go-down


8. Cherian P, Kumarasinghe P: Giant basal cell carcinoma masquerading as an osteogenic sarcoma. Australas J Dermatol; 2009 Feb;50(1):60-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma masquerading as an osteogenic sarcoma.
  • Superficial and deep biopsies yielded invasive basal cell carcinoma.
  • We explore the literature regarding the tumorigenic effects of peri-fracture cytokines on the biological behaviour of basal cell neoplasms.
  • [MeSH-major] Bone Neoplasms / diagnosis. Carcinoma, Basal Cell / diagnosis. Clavicle / injuries. Fractures, Bone / complications. Osteosarcoma / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Fractures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178496.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


9. Bohn AA, Wills T, Caplazi P: Basal cell tumor or cutaneous basilar epithelial neoplasm? Rethinking the cytologic diagnosis of basal cell tumors. Vet Clin Pathol; 2006 Dec;35(4):449-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell tumor or cutaneous basilar epithelial neoplasm? Rethinking the cytologic diagnosis of basal cell tumors.
  • The cytologic interpretation was malignant neoplasia with histiocytic inflammation.
  • Differentials included a carcinoma or, given the melanin pigment and variable morphology of the cells, possibly malignant melanoma.
  • Histologically, the tumor was diagnosed as a basal cell epithelioma.
  • Neoplasms that once were lumped into the broad histologic diagnosis of basal cell tumors have since been split into distinct entities, dependent on evidence of differentiation into epidermis, trichofollicular epithelium, or sweat or sebaceous glands.
  • Although histologic reclassification has resulted in removal of most of these entities from the original basal cell tumor category, a cytologic diagnosis of basal cell tumor continues to be used to represent the large, heterogeneous group of epidermal, trichofollicular, and adnexal skin tumors with basal cell characteristics.
  • The case in this report demonstrates the heterogeneity of neoplasms that may be diagnosed cytologically as basal cell tumors and supports the need for cytologic criteria and nomenclature that better reflect potential variation in tissue differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123253.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Komorski JA, Nienartowicz JM: [Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis]. Otolaryngol Pol; 2009 Sep-Oct;63(5):442-7
Genetic Alliance. consumer health - Acinic Cell Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis].
  • [Transliterated title] Acinic cell carcinoma ślinianki przyusznej o nietypowym obrazie klinicznym i niekorzystnym przebiegu.
  • In the case of neck tumours, these are unfortunately late signs, but in patients with a primary neoplastic focus within the head and neck, neck tumour is often the first sign of the disease.
  • The authors describe a clinical case of neck tumour with initially unclear etiology.
  • The preoperative diagnostics including ultrasonography, thin-needle puncture, MRI, carotid angiography and videostroboscopy was significant for surgical treatment planning; yet it was the intraoperative clinical picture which indicated that the tumour derived from the inferior parotid pole.
  • The histopathological examination confirmed non-cornifying basal cell epithelioma only in the essential lesion with no metastases to lymph nodes and surrounding tissue margins free of infiltrates.
  • Two and a half years after the procedure, the patient presented with a tumour localized on the front thoracic wall and two rapidly enlarging tumours in the nape of the neck.
  • In the collected specimen of the tumour on the front thoracic wall, a diagnosis of acinic cell carcinoma was made.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / surgery. Parotid Neoplasms / pathology. Parotid Neoplasms / surgery
  • [MeSH-minor] Aged. Head and Neck Neoplasms / secondary. Humans. Male. Neck Dissection / methods. Neoplasm Staging. Palliative Care. Prognosis. Thoracic Wall / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169911.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


11. Luebke AM, Schlomm T, Gunawan B, Bonkhoff H, Füzesi L, Erbersdobler A: Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach. Virchows Arch; 2005 Mar;446(3):338-41
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach.
  • Basal cell tumours of the prostatic gland are rare, and the classification is difficult.
  • In the present case report, a large, tumour-like proliferation of atypical basaloid cells was found incidentally in a prostatectomy specimen that otherwise contained a conventional acinar adenocarcinoma.
  • However, there were no definite criteria for a malignant behaviour of the basal cell tumour.
  • Comparative genomic hybridisation from microdissected tumour cells yielded losses at the short arms of chromosomes 8 and 12 in the conventional adenocarcinoma and a normal karyotype in the basal cell tumour.
  • The pathological findings favoured the diagnosis of an atypical basal cell hyperplasia.
  • [MeSH-major] Carcinoma, Acinar Cell / complications. Carcinoma, Acinar Cell / pathology. Prostatic Hyperplasia / complications. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / complications. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Basal Cell / genetics. Neoplasms, Basal Cell / pathology. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1993 Aug;117(8):799-801 [8343043.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):342-7 [7529134.001]
  • [Cites] Eur Urol. 1999;36(1):21-30 [10364651.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):668-72 [14999772.001]
  • [Cites] Histopathology. 1992 Feb;20(2):151-5 [1559669.001]
  • [Cites] Pathol Res Pract. 1990 Feb;186(1):28-36 [2179908.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):645-59 [7686348.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):231-43 [7522536.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):202-8 [11161378.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):612-29 [9195581.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):787-91 [14756145.001]
  • [Cites] Hum Pathol. 1988 Dec;19(12):1425-33 [2461340.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1523-9 [14657711.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):399-406 [11159178.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):43-51 [12107088.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1205-14 [1281386.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1225-33 [2400973.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1447-50 [9865831.001]
  • (PMID = 15726402.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Rudolph J, Berl J, Hamm B, Klingebiel R: Magnetic resonance imaging findings of basal cell adenoma in Curschmann-Steinert myotonic dystrophy. Acta Radiol; 2006 Mar;47(2):205-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging findings of basal cell adenoma in Curschmann-Steinert myotonic dystrophy.
  • We present the magnetic resonance imaging in the unusual combination of a patient with known myotonic dystrophy and recurrent basal cell tumor.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Basal Cell / diagnosis. Head and Neck Neoplasms / diagnosis. Magnetic Resonance Imaging. Myotonic Dystrophy / pathology

  • Genetic Alliance. consumer health - Myotonic dystrophy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604969.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


13. Allali J, D'Hermies F, Renard G: Basal cell carcinomas of the eyelids. Ophthalmologica; 2005 Mar-Apr;219(2):57-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinomas of the eyelids.
  • Basal cell carcinomas (BCC) are the more frequent malignant tumors seen in France as in other western countries.
  • BCC is the most common cause leading to eyelid reconstructive surgery; a surgery which has a triple objective: tumor removal, functionality and an esthetic outcome.
  • [MeSH-major] Carcinoma, Basal Cell. Eyelid Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15802929.001).
  • [ISSN] 0030-3755
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 141
  •  go-up   go-down


14. Kilic E, Milde-Langosch K, Müller V, Wirtz R, Ihnen M: [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy]. Pathologe; 2008 Nov;29 Suppl 2:347-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy].
  • [Transliterated title] Expression des "activated leukocyte cell adhesion molecule" im Mammakarzinom. Prädiktivität für das Ansprechen auf eine taxanfreie Chemotherapie.
  • AIMS: Activated leukocyte cell adhesion molecule (ALCAM) is a cell surface immunoglobulin expressed in breast cancer (BC) and is assumed to be implicated in tumourigenesis and tumour progression.
  • RESULTS: In the normal breast ALCAM is expressed in luminal and basal epithelial cells.
  • [MeSH-major] Antigens, CD / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / genetics. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Cell Adhesion Molecules, Neuronal / genetics. Fetal Proteins / genetics. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / genetics. Taxoids / administration & dosage
  • [MeSH-minor] Blotting, Western. Breast / pathology. Chemotherapy, Adjuvant. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Kaplan-Meier Estimate. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Predictive Value of Tests. Prognosis. RNA, Messenger / genetics. Receptors, Estrogen / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Oct 1;98(7):2134-42 [11568000.001]
  • [Cites] Med Sci Monit. 2006 Jul;12(7):BR245-56 [16810131.001]
  • [Cites] Eur J Cell Biol. 2002 Jun;81(6):313-21 [12113472.001]
  • [Cites] Onkologie. 2003 Oct;26(5):438-45 [14605459.001]
  • [Cites] Med Sci Monit. 2006 Aug;12(8):BR263-73 [16865058.001]
  • [Cites] Breast Cancer Res. 2004;6(5):R478-87 [15318930.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):769-74 [10702391.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1160-4 [15509676.001]
  • [Cites] J Pathol. 2005 Feb;205(3):359-76 [15532095.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 27;267(3):870-4 [10673383.001]
  • [Cites] Int J Cancer. 1999 Oct 22;84(5):533-8 [10502734.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):229-38 [11373098.001]
  • [Cites] Cell Mol Life Sci. 2007 Dec;64(24):3201-18 [17957337.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):403-9 [16484444.001]
  • [Cites] Oncology. 2005;68(4-6):462-70 [16024937.001]
  • (PMID = 18810438.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ALCAM protein, human; 0 / Antigens, CD; 0 / Cell Adhesion Molecules, Neuronal; 0 / Fetal Proteins; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Taxoids
  •  go-up   go-down


15. Schulz H: [Pigmented lesion on the temple. Pigment cell tumor, basal cell carcinoma, or irritated seborrheic keratosis?]. Hautarzt; 2010 Dec;61(12):1061-2
Genetic Alliance. consumer health - Keratosis, seborrheic.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pigmented lesion on the temple. Pigment cell tumor, basal cell carcinoma, or irritated seborrheic keratosis?].
  • [Transliterated title] Pigmentierte Läsion der Schläfenregion. Melanozytärer Tumor, Basalzellkarzinom oder irritierte seborrhoische Keratose?
  • The slightly raised skin tumor with well-defined margins had appeared 3 years earlier, slowly enlarging and finally changing in color.
  • Biopsy of the tumor demonstrated hyperplasia of the epidermis and normal basaloid keratinocytes partially extending into the dermis.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Facial Dermatoses / diagnosis. Facial Neoplasms / diagnosis. Keratosis, Seborrheic / diagnosis. Nevus, Pigmented / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Clin. 2001 Apr;19(2):347-57 [11556243.001]
  • [Cites] Arch Dermatol. 2002 Dec;138(12):1556-60 [12472342.001]
  • (PMID = 21069503.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Xu E, Wang X, Hao Z, Chen Z, Lu X: Germinoma in the basal ganglia with an abnormal karyotype: case report and review of the literature. Childs Nerv Syst; 2010 May;26(5):707-12
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germinoma in the basal ganglia with an abnormal karyotype: case report and review of the literature.
  • INTRODUCTION: Germ cell tumor of basal ganglia with abnormal constitutional karyotype has been rarely reported.
  • Magnetic resonance imaging showed high intensity on T1-weighted, T2-weighted, and contrast-enhanced T1-weighted images in the left basal ganglia and ipsilateral cerebral hemiatrophy predominantly in the basal ganglia and midbrain.
  • Germinoma in the left basal ganglia was confirmed by stereotactic biopsy and immunochemical examination.
  • His constitutional karyotype was 46, XY, t (8; 19), (p23.1; p13.1), a novel chromosomal abnormality.
  • DISCUSSION: Intracranial germinoma, a potentially curable tumor, should be considered in children with nonspecific neurological symptoms, endocrinologic changes, and ipsilateral cerebral hemiatrophy on computed tomography or magnetic resonance.
  • Investigation of chromosomal aberrations in those patients would clarify the tumorigenesis and lead to possibilities for novel disease-specific therapies.
  • [MeSH-major] Basal Ganglia Diseases / genetics. Brain Neoplasms / genetics. Germinoma / genetics

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Apr 1;71(7):2306-11 [8453551.001]
  • [Cites] Mod Pathol. 2006 Jun;19(6):864-73 [16607373.001]
  • [Cites] Hum Genet. 1995 Dec;96(6):644-50 [8522320.001]
  • [Cites] Pediatr Neurosurg. 2000 Nov;33(5):261-264 [11155064.001]
  • [Cites] Surg Neurol. 1997 Jan;47(1):28-31 [8986161.001]
  • [Cites] Neuroradiology. 1998 Aug;40(8):507-11 [9763338.001]
  • [Cites] J Pathol. 1999 Nov;189(3):387-93 [10547601.001]
  • [Cites] Pediatr Radiol. 2006 Apr;36(4):325-30 [16463029.001]
  • [Cites] Childs Nerv Syst. 1997 Oct;13(10):563-6 [9403208.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Mar;87(1):29-33 [8646736.001]
  • [Cites] AJNR Am J Neuroradiol. 1983 May-Jun;4(3):478-80 [6410776.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Dec;129(6):698-704 [14663438.001]
  • [Cites] Childs Nerv Syst. 2006 Dec;22(12):1513-8 [17053934.001]
  • [Cites] J Neurosurg Pediatr. 2008 Aug;2(2):118-24 [18671616.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):177-9 [16700048.001]
  • [Cites] Pediatr Neurosurg. 2004 Nov-Dec;40(6):306-11 [15821363.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Mar;27(3):244-51 [10679913.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):803-8 [15936563.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):579-86 [10934160.001]
  • [Cites] Oncology (Williston Park). 2005 May;19(6):705-11; discussion 711-2, 715-7, 721 [15971448.001]
  • [Cites] J Neurosurg. 2005 May;102(5):897-901 [15926716.001]
  • [Cites] Arch Neurol. 1991 Jun;48(6):652-7 [2039390.001]
  • [Cites] Surg Neurol. 2000 May;53(5):432-7; discussion 437-8 [10874141.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1204-10 [16775265.001]
  • [Cites] World J Gastroenterol. 2007 Feb 21;13(7):1090-7 [17373745.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3479-82 [11719392.001]
  • [Cites] Acta Neurochir (Wien). 2002 Feb;144(2):145-50; discussion 150 [11862514.001]
  • [Cites] Cancer. 1998 May 1;82(9):1749-55 [9576298.001]
  • [Cites] Acta Pathol Jpn. 1986 Jan;36(1):143-9 [3962671.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):215-8 [12675314.001]
  • [Cites] Neuroradiology. 2002 May;44(5):389-94 [12012122.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Mar;32(3):163-5 [1377800.001]
  • [Cites] J Pathol. 2000 Jun;191(2):187-92 [10861580.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):210-22 [15738984.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 May;26(5):1166-9 [15891178.001]
  • [Cites] Childs Nerv Syst. 1990 Jan;6(1):3-7 [2178773.001]
  • [Cites] J Neurooncol. 2009 Mar;92(1):37-44 [18953691.001]
  • [Cites] Pediatr Neurosurg. 1998 Oct;29(4):199-202 [9876249.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):815-21 [11005262.001]
  • (PMID = 19876633.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


17. González F, García A: [Periocular basal cell carcinoma]. Arch Soc Esp Oftalmol; 2005 May;80(5):275-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Periocular basal cell carcinoma].
  • [Transliterated title] Carcinoma basocelular periocular.
  • PURPOSE: Brief review of basal cell carcinomas (BCCs) of the periocular area.
  • [MeSH-major] Carcinoma, Basal Cell. Eyelid Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918094.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 49
  •  go-up   go-down


18. Braun RP, Klumb F, Girard C, Bandon D, Salomon D, Skaria A, Adatto M, French LE, Saurat JH, Vallée JP: Three-dimensional reconstruction of basal cell carcinomas. Dermatol Surg; 2005 May;31(5):562-6; discussion 566-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional reconstruction of basal cell carcinomas.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common type of skin cancer.
  • One of the main problems with BCC is the risk of local recurrence of the tumor after treatment.
  • OBJECTIVE: To better understand the tumor morphology and growth pattern of BCC, we tried to develop a method that provides a precise three-dimensional model of the tumor.
  • METHODS: Because Mohs surgery provides the best overview of the tumor and the tumor margins (both lateral and in depth), the reconstruction was based on slides from Mohs surgery.
  • After digitization and processing of the slides, the tumor was then surrounded by a Mohs surgeon on a computer screen.
  • These selections (lines) were used for a three-dimensional reconstruction of the tumor using MedSurf3D software.
  • CONCLUSIONS: Three-dimensional reconstruction is a fascinating tool that might improve our understanding of the behavior, growth pattern, and tumor morphology of BCCs.
  • This technique might also be useful in other fields of cutaneous oncology, such as the calculation of the tumor volume of melanomas.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Mohs Surgery / methods. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962742.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


19. Grønbaek K, Guldberg P: [Acquired mutations--basic cancer biology]. Ugeskr Laeger; 2006 Jun 12;168(24):2335-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Erhvervede mutationer--basal cancerbiologi.
  • It is now well-established that cancer is a genetic disease, although in most cases not inherited.
  • A sporadic cancer develops when a somatic cell acquires specific growth advantages through successive accumulation of changes in cancer genes, including oncogenes, tumor suppressor genes and stability genes.
  • Herein, we give a brief overview of the basic genetic changes in cancer and discuss how specific gene alterations may contribute to the development of malignant melanoma.
  • [MeSH-major] Mutation / genetics. Neoplasms / genetics
  • [MeSH-minor] Genes, Tumor Suppressor. Humans. Melanoma / genetics. Models, Genetic. Neoplasm Metastasis / genetics. Oncogenes / genetics. Skin Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16822414.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


20. Evke E, Minbay FZ, Temel SG, Kahveci Z: Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval. J Mol Histol; 2009 Feb;40(1):13-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval.
  • p53 is the most frequently altered tumor-suppressor gene in skin cancer.
  • In contrast, the mutant p53 protein has an extended half-life in tumor cells and can be detected by immunohistochemical methods. p53 is widely used as an indicator of tumor aggression and progression.
  • This study was designed to evaluate the efficacy of different fixatives, of microwaving and microwave pretreatment method to retrieve p53 immunoreactivity in paraffin-embedded non-lesioned (adjacent normal tissue) human skin samples or pathological human skin samples diagnosed as basal cell carcinoma.
  • In this study the effects of six different fixation methods on the immunohistochemical staining have been investigated in basal cell tumor specimens.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Immunohistochemistry / methods. Microwaves. Skin Neoplasms / metabolism. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 Nov 30;333(22):1507-8 [7477163.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4407-11 [7753819.001]
  • [Cites] Histochem J. 1988 Jun-Jul;20(6-7):323-8 [3065303.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):839-44 [2228312.001]
  • [Cites] Biotech Histochem. 2005 May-Aug;80(3-4):123-32 [16298897.001]
  • [Cites] Acta Histochem. 2006;107(6):421-34 [16256175.001]
  • [Cites] J Neurosci Methods. 1994 Dec;55(2):183-90 [7723382.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1785-9 [1717923.001]
  • [Cites] J Microsc. 2000 Jan;197(Pt 1):101-6 [10620153.001]
  • [Cites] Methods Mol Biol. 2003;234:231-43 [12824536.001]
  • [Cites] Nature. 1997 May 15;387(6630):299-303 [9153396.001]
  • [Cites] Biotech Histochem. 2006 Mar-Jun;81(2-3):63-9 [16908430.001]
  • [Cites] Br J Dermatol. 1993 Mar;128(3):237-41 [8471506.001]
  • [Cites] Micron. 1994;25(2):151-70 [8055246.001]
  • [Cites] Eur J Dermatol. 2006 Sep-Oct;16(5):543-7 [17101476.001]
  • [Cites] Am J Clin Pathol. 1994 Nov;102(5):665-70 [7942634.001]
  • [Cites] Nature. 1997 May 15;387(6630):296-9 [9153395.001]
  • [Cites] Am J Clin Pathol. 1994 Feb;101(2):177-80 [8116572.001]
  • [Cites] Histochem J. 1988 Jun-Jul;20(6-7):313-22 [2464564.001]
  • [Cites] J Neurosci Methods. 2006 Sep 30;156(1-2):154-60 [16621014.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2649-54 [8653711.001]
  • [Cites] Scanning. 1993 Mar-Apr;15(2):88-98 [8287207.001]
  • [Cites] Biotech Histochem. 2001 Sep-Nov;76(5-6):233-7 [11871743.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):217-22 [10757331.001]
  • [Cites] Br Med Bull. 1997;53(3):522-38 [9374035.001]
  • [Cites] Biotech Histochem. 1997 May;72(3):144-7 [9187737.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1389-97 [7901994.001]
  • [Cites] EMBO J. 1999 Mar 15;18(6):1660-72 [10075936.001]
  • [Cites] Histochem J. 1988 Jun-Jul;20(6-7):373-87 [2464568.001]
  • [Cites] J Microsc. 1998 Nov;192(Pt 2):212-6 [9853377.001]
  • [Cites] Biotech Histochem. 2003 Apr;78(2):119-28 [14533848.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Eur J Morphol. 2001 Dec;39(5):313-7 [12221513.001]
  • [Cites] Histopathology. 1993 Jan;22(1):45-50 [8436341.001]
  • [Cites] Am J Clin Pathol. 1992 Feb;97(2):244-9 [1546693.001]
  • [Cites] FASEB J. 2002 Mar;16(3):420-2 [11790725.001]
  • [Cites] J Histochem Cytochem. 1997 Mar;45(3):327-43 [9071315.001]
  • (PMID = 19096907.001).
  • [ISSN] 1567-2387
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 1HG84L3525 / Formaldehyde; 3K9958V90M / Ethanol
  •  go-up   go-down


21. Boran C, Parlak AH, Erkol H: Collision tumour of trichofolliculoma and basal cell carcinoma. Australas J Dermatol; 2007 May;48(2):127-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumour of trichofolliculoma and basal cell carcinoma.
  • Histopathological examination revealed that the nodule was composed of trichofolliculoma and basal cell carcinoma.
  • There was no transitional zone between the two neoplasms.
  • The diagnosis was made as a collision tumour of trichofolliculoma and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Facial Neoplasms / pathology. Hair Follicle / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Trichofolliculoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535204.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


22. Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, Pereira EM, Lakhani SR, Schmitt FC: Metaplastic breast carcinomas are basal-like tumours. Histopathology; 2006 Jul;49(1):10-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metaplastic breast carcinomas are basal-like tumours.
  • AIMS: Recently, an immunohistochemical panel comprising antibodies against HER2, oestrogen receptor (ER), epidermal growth factor receptor (EGFR) and cytokeratin (CK) 5/6 was reported to identify basal-like breast carcinomas, as defined by cDNA microarrays.
  • Our aim was to analyse a series of metaplastic breast carcinomas (MBCs) using this panel plus two other basal markers (CK14 and p63) and progesterone receptor (PR), to define how frequently MBCs show a basal-like immunophenotype.
  • All but six cases (91%) showed the typical immunoprofile of basal-like tumours (ER- and HER2-, EGFR+ and/or CK5/6+).
  • When CK14 and p63 were added to the panel, two additional cases could be classified as basal-like.
  • CONCLUSIONS: Our results demonstrate that MBCs show a basal-like phenotype, regardless of the type of metaplastic elements.
  • Moreover, as these neoplasms frequently overexpress EGFR (57%), patients with MBC may benefit from treatment with anti-EGFR drugs.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Keratins / metabolism. Membrane Proteins / metabolism. Metaplasia. Neoplasms, Basal Cell / classification. Neoplasms, Basal Cell / metabolism. Neoplasms, Basal Cell / pathology. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16842242.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 68238-35-7 / Keratins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


23. Vidal VP, Ortonne N, Schedl A: SOX9 expression is a general marker of basal cell carcinoma and adnexal-related neoplasms. J Cutan Pathol; 2008 Apr;35(4):373-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SOX9 expression is a general marker of basal cell carcinoma and adnexal-related neoplasms.
  • In the hair follicle SOX9 is expressed in the outer layer of the epithelial sheath, and the hair stem cell compartment.
  • Activation of the Shh pathway is a major cause of cutaneous basal cell carcinoma (BCC).
  • Here we test whether activation of SOX9 is a general feature of BCC, or whether it could be used as a biomarker to better define subtypes of these skin tumors.
  • Staining was heterogeneous and could be detected among the basaloid cells of the palisading cell layer as well as in the tumour nest.
  • SOX9 expression was detected in all adnexal tumors analyzed and absent in Bowen's disease and Merkel tumor.
  • CONCLUSIONS: SOX9 expression is a general feature of BCC and adnexal skin neoplasms, suggesting a contribution of SOX9 to the pathogenesis of these tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / metabolism. High Mobility Group Proteins / metabolism. Neoplasms, Adnexal and Skin Appendage / metabolism. Skin Neoplasms / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333897.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / High Mobility Group Proteins; 0 / SOX9 Transcription Factor; 0 / SOX9 protein, human; 0 / Transcription Factors
  •  go-up   go-down


24. Belliveau MJ, Coupal DJ, Brownstein S, Jordan DR, Prokopetz R: Infundibulocystic basal cell carcinoma of the eyelid in basal cell nevus syndrome. Ophthal Plast Reconstr Surg; 2010 May-Jun;26(3):147-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infundibulocystic basal cell carcinoma of the eyelid in basal cell nevus syndrome.
  • PURPOSE: To describe the histopathologic findings in a series of eyelid basal cell carcinomas removed from patients with basal cell nevus syndrome.
  • METHODS: Retrospective case series of 5 patients with basal cell nevus syndrome identified from our oculoplastics service.
  • The pertinent published literature on basal cell nevus syndrome and eyelid basal cell carcinoma was reviewed.
  • Twenty-three of these lesions were basal cell carcinomas.
  • The infundibulocystic variant of basal cell carcinoma was identified most commonly (57%).
  • CONCLUSIONS: Eyelid basal cell carcinomas in patients with basal cell nevus syndrome were commonly of the infundibulocystic variety in our series.
  • Infundibulocystic basal cell carcinomas, which can be clinically indistinguishable from the more common forms, are thought to be less aggressive than other types of basal cell carcinoma and are a reassuring histopathologic diagnosis.
  • It is important for the ophthalmologist and pathologist to be aware of infundibulocystic basal cell carcinomas, as they are more common in patients with basal cell nevus syndrome and may be a clue to the diagnosis of this autosomal dominant cancer-predisposition syndrome or other associated syndromes.
  • To our knowledge, this variant of basal cell carcinoma has not been previously discussed in the ophthalmic literature.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology


25. McPherson T, Ogg G: Spontaneous resolution of basal cell carcinoma in naevoid basal cell carcinoma syndrome/Gorlin's syndrome. Clin Exp Dermatol; 2009 Dec;34(8):e884-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous resolution of basal cell carcinoma in naevoid basal cell carcinoma syndrome/Gorlin's syndrome.
  • We describe a 10-year-old patient with naevoid basal cell carcinoma syndrome (NBCCS) which was diagnosed when she was 3 years old.
  • She has developed multiple basal cell carcinomas (BCCs) over this time, in particular on her face and trunk.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Child. Female. Humans. Neoplasm Regression, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055856.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Chuprov IN: [Basal-cell carcinoma of the skin]. Arkh Patol; 2007 Nov-Dec;69(6):52-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal-cell carcinoma of the skin].
  • The paper represents an overview of updated literature concerning common skin neoplasms.
  • The clinical manifestation of the basal cell carcinoma varies significantly according to the patients age, tumor size, localization and duration of the neoplastic process, histological type of the tumor, including proliferative activity and stromal reactions.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18290385.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


27. Barry J, Oon SF, Watson R, Barnes L: The management of basal cell carcinomas. Ir Med J; 2006 Jun;99(6):179-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of basal cell carcinomas.
  • The mortality and morbidity associated with basal cell carcinoma (BCC) is low.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Medical Audit. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921825.001).
  • [ISSN] 0332-3102
  • [Journal-full-title] Irish medical journal
  • [ISO-abbreviation] Ir Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


28. Warshaw EM, Lederle FA, Grill JP, Gravely AA, Bangerter AK, Fortier LA, Bohjanen KA, Chen K, Lee PK, Rabinovitz HS, Johr RH, Kaye VN, Bowers S, Wenner R, Askari SK, Kedrowski DA, Nelson DB: Accuracy of teledermatology for pigmented neoplasms. J Am Acad Dermatol; 2009 Nov;61(5):753-65
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of teledermatology for pigmented neoplasms.
  • OBJECTIVE: We sought to compare accuracy of store-and-forward teledermatology for pigmented neoplasms with standard, in-person clinic dermatology.
  • METHODS: We conducted a repeated measures equivalence trial involving veterans with pigmented skin neoplasms.
  • In contrast to diagnostic accuracy, rates of appropriate management plans for teledermatology were superior and/or equivalent to clinic dermatology (all image types: all lesions, and benign lesions).
  • However, for the subgroup of malignant lesions (n = 124), the rate of appropriate management was significantly worse for teledermatology than for clinic dermatology (all image types).
  • However, for the important subgroup of malignant pigmented lesions, both diagnostic and management accuracy of teledermatology was generally inferior to clinic dermatology and up to 7 of 36 index melanomas would have been mismanaged via teledermatology.
  • Teledermatology and teledermatoscopy should be used with caution for patients with suspected malignant pigmented lesions.
  • [MeSH-major] Dermatology / standards. Melanoma / diagnosis. Nevus, Pigmented / diagnosis. Skin Neoplasms / diagnosis. Telemedicine / standards
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cross-Sectional Studies. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Reproducibility of Results. Skin Diseases / diagnosis. Young Adult

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Am Acad Dermatol. 2010 Feb;62(2):319
  • (PMID = 19679375.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


29. Asplund A, Gry Björklund M, Sundquist C, Strömberg S, Edlund K, Ostman A, Nilsson P, Pontén F, Lundeberg J: Expression profiling of microdissected cell populations selected from basal cells in normal epidermis and basal cell carcinoma. Br J Dermatol; 2008 Mar;158(3):527-38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of microdissected cell populations selected from basal cells in normal epidermis and basal cell carcinoma.
  • BACKGROUND: Basal cell carcinomas (BCCs) are prevalent tumours with uniform histology that develop without any known precursor lesion.
  • METHODS: We used laser-assisted microdissection to isolate and collect cell populations defined under the microscope.
  • Peripheral cells from nests of BCC were selected to represent tumour cells, and normal keratinocytes from epidermis basal layer were used as control.
  • Furthermore, tumour cells appear to have an increased sensitivity to oxygen radicals and dysregulated genes involved in antigen presentation.
  • We found that expression patterns were significantly altered in BCC cells compared with basal keratinocytes and that the Wnt signalling pathway was upregulated in tumour cells.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Keratinocytes / metabolism. Receptors, Cell Surface / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18241271.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


30. Lewis JE: Keloidal basal cell carcinoma. Am J Dermatopathol; 2007 Oct;29(5):485
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keloidal basal cell carcinoma.
  • Herein is reported a third case of keloidal basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Keloid / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890922.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-34-5 / Collagen
  •  go-up   go-down


31. Abenoza P, Kowalczyk J, Nousari CH: Basal cell carcinoma-associated paratumoral follicular and epidermal hyperplasia. Am J Dermatopathol; 2010 Jun;32(4):348-51
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma-associated paratumoral follicular and epidermal hyperplasia.
  • Reactive epithelial hyperplasia is a well-known phenomenon which occurs adjacent to certain neoplasms such as cutaneous fibrous histiocytoma, granular cell tumor, Spitz nevus, and melanoma.
  • We report 46 cases of paratumoral follicular and epidermal hyperplasia associated with basal cell carcinoma (BCC).
  • It may resemble other tumors such as squamous cell carcinoma and may appear in sections where BCC is absent.
  • The recognition of this entity may help dermatopathologists avoid misdiagnosing this process as a tumor and can suggest further search (section through the block or rebiopsy) when this reactive phenomenon is seen in sections without the associated BCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Diseases / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / pathology. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2011 Feb;33(1):107 [21239900.001]
  • (PMID = 20145534.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Koutlas IG, Koch CA, Vickers RA, Brouwers FM, Vortmeyer AO: An unusual ostensible example of intraoral basal cell carcinoma. J Cutan Pathol; 2009 Apr;36(4):464-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual ostensible example of intraoral basal cell carcinoma.
  • An example of oral basal cell carcinoma is presented originating on the posterior mandibular mucosa and gingiva of a 67-year-old female.
  • Tissue samples of the tumor were evaluated with monoclonal antibody Ber-EP4 and were compared with examples of oral mucosa, skin, oral and cutaneous squamous cell carcinoma, peripheral ameloblastoma, ameloblastoma and cutaneous basal cell carcinoma (BCC).
  • Only neoplastic basal cells showed positive immunohistochemical staining.
  • These observations support the inclusion of BCC in the differential diagnosis of appropriate oral mucosal neoplasms.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Mouth Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Loss of Heterozygosity. Receptors, Cell Surface / genetics

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278434.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Cell Surface; 0 / human epithelial antigen-125; 0 / patched receptors
  •  go-up   go-down


33. Cuevas J, de Eusebio E, Diez E, Castiñeira I: [Mohs micrographic surgery: aplication of this technique to penile neoplasms]. Actas Urol Esp; 2007 Oct;31(9):1076-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mohs micrographic surgery: aplication of this technique to penile neoplasms].
  • [Transliterated title] Cirugía de Mohs: aplicación de la técnica a neoplasias del pene.
  • That is possible because Mohs surgery provides the advantage of microscopically controlled tumor-free borders in each stage guiding the surgeon in the tumor persistence until the complete surgical excision.
  • Mohs micrographic surgery is a precise treatment for penile neoplasms and its utility is justified because the removal of a substantial surgical margin of normal tissue is obviated.
  • Although infrequent, other penile neoplasms that can benefit from Mohs micrographic surgery are: basal cell carcinoma, extrammamary Paget's disease, in situ melanoma and granular cell tumor.
  • [MeSH-major] Mohs Surgery / methods. Penile Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18257374.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 17
  •  go-up   go-down


34. Misago N, Satoh T, Miura Y, Nagase K, Narisawa Y: Merkel cell-poor trichoblastoma with basal cell carcinoma-like foci. Am J Dermatopathol; 2007 Jun;29(3):249-55
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell-poor trichoblastoma with basal cell carcinoma-like foci.
  • We reexamined 11 cases of trichoblastoma, and two cases of trichoblastoma with basal cell carcinoma (BCC)-like foci were found.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Hair Diseases / pathology. Hair Follicle / pathology. Merkel Cells / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Keratin-15 / analysis. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519622.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-15
  •  go-up   go-down


35. Scalvenzi M, Lembo S, Francia MG, Balato A: Dermoscopic patterns of superficial basal cell carcinoma. Int J Dermatol; 2008 Oct;47(10):1015-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopic patterns of superficial basal cell carcinoma.
  • BACKGROUND: Superficial basal cell carcinoma (BCC) presents as a scaly, pink to red-brown patch and is predominantly located on the trunk.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Dermoscopy. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18986346.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Yu L, Galan A, McNiff JM: Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma. J Cutan Pathol; 2009 Oct;36(10):1074-176
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma.
  • BACKGROUND: Superficial skin biopsies of basal cell carcinoma (BCC) represent some of the most common dermatopathology specimens.
  • Superficial shave biopsies containing partial samples of lesions with squamatization present difficulties in distinguishing BCC from squamous cell carcinoma (SCC).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 John Wiley & Sons A/S.
  • (PMID = 19187107.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125
  •  go-up   go-down


37. Eslami B, Lorente C, Kieff D, Caruso PA, Faquin WC: Ameloblastoma associated with the nevoid basal cell carcinoma (Gorlin) syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jun;105(6):e10-3
Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ameloblastoma associated with the nevoid basal cell carcinoma (Gorlin) syndrome.
  • Nevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant disorder characterized by a wide range of clinical signs and symptoms.
  • The major criteria for the diagnosis are multiple cutaneous basal cell carcinomas, multiple odontogenic keratocysts of the jaw, palmar and plantar pits, and skeletal abnormalities.
  • [MeSH-major] Ameloblastoma / etiology. Basal Cell Nevus Syndrome / complications. Jaw Neoplasms / complications. Maxillary Neoplasms / etiology
  • [MeSH-minor] Aged. Chromosomes, Human, Pair 9. Female. Humans. Receptors, Cell Surface / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417377.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


38. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E, Kerl H: Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol; 2007 Dec;157 Suppl 2:47-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology and aetiology of basal cell carcinoma.
  • Basal cell carcinoma (BCC) is a malignant epithelial neoplasm of the skin preferentially affecting male caucasians and is rarely observed in patients with more intense skin pigmentation.
  • Epidemiological data indicate that the overall incidence is increasing worldwide significantly by about 3-10% per annum.(1-3) Based on the increasing incidence of this usually not life-threatening tumour BCC appears to develop into a growing public health problem.
  • This review elucidates the risk factors for the development and for the progression of BCC leading to an improved understanding of this tumour.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Disease Progression. Humans. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067632.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 66
  •  go-up   go-down


39. Prabhakaran VC, Gupta A, Huilgol SC, Selva D: Basal cell carcinoma of the eyelids. Compr Ophthalmol Update; 2007 Jan-Feb;8(1):1-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the eyelids.
  • Basal cell carcinoma is the most common malignancy in humans, and it is also the most frequent periocular malignancy.
  • Although a slow-growing tumor, it can lead to significant morbidity in the periocular region as a result of orbital invasion.
  • Management needs to be individualized, taking into account patient factors, tumor characteristics, and histological subtype.
  • In this review, we discuss the risk factors, pathology, molecular biology, clinical features, and management of eyelid basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell. Eyelid Neoplasms
  • [MeSH-minor] Australia / epidemiology. Combined Modality Therapy. Diagnosis, Differential. Humans. Incidence. Neoplasm Invasiveness. Orbital Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Compr Ophthalmol Update. 2007 Jan-Feb;8(1):15-6 [17394755.001]
  • (PMID = 17394754.001).
  • [ISSN] 1527-7313
  • [Journal-full-title] Comprehensive ophthalmology update
  • [ISO-abbreviation] Compr Ophthalmol Update
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 119
  •  go-up   go-down


40. Szeimies RM: Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. Dermatol Clin; 2007 Jan;25(1):89-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma.
  • Basal cell carcinomas (BCCs) are the most common malignant tumors of the skin.
  • Treatment of BCCs should be chosen according to clinical type, tumor size, and location.
  • MAL is licensed in Europe, Australia, New Zealand, and Brazil for the treatment of actinic keratoses, Bowen's disease, and nodular and superficial BCC.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126746.001).
  • [ISSN] 0733-8635
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 19
  •  go-up   go-down


41. Rossman D, Arthurs B, Odashiro A, Saraiva V, Burnier M Jr: Basal cell carcinoma of the caruncle. Ophthal Plast Reconstr Surg; 2006 Jul-Aug;22(4):313-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the caruncle.
  • Surgical excision of the lesion was performed, and histopathology showed a nodular basal cell carcinoma of the caruncle.
  • No tumor recurrence was detected in the caruncle after 6 months of follow-up.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Conjunctival Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855514.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Dixon AJ: Multiple superficial basal cell carcinomata--topical imiquimod versus curette and cryotherapy. Aust Fam Physician; 2005 Jan-Feb;34(1-2):49-52
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple superficial basal cell carcinomata--topical imiquimod versus curette and cryotherapy.
  • BACKGROUND: Superficial basal cell carcinoma can be successfully managed by means other than surgical excision.
  • OBJECTIVE: This article discusses the management of an insulin dependent diabetic man aged 52 years presenting with 17 torso basal cell carcinomas (BCCs); mostly superficial BCCs (SBCCs).
  • [MeSH-major] Aminoquinolines / therapeutic use. Carcinoma, Basal Cell / therapy. Cryotherapy. Curettage. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15727358.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


43. Shulman O, Laitman Y, Vilan A, Leviav A, Friedman E: Monoclonal origin of anatomically distinct basal cell carcinomas. J Invest Dermatol; 2006 Mar;126(3):676-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal origin of anatomically distinct basal cell carcinomas.
  • Basal cell carcinoma (BCC) is the most common skin tumor in Caucasians.
  • An identical X-chromosome inactivation pattern was noted in all four tumors taken from one patient, and in another informative patient, one tumor demonstrated LOH and the other retained it.
  • We conclude that the majority of anatomically distinct BCCs are monoclonal neoplasms and may represent expansion of the same clone.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Loss of Heterozygosity. Skin Neoplasms / genetics. X Chromosome Inactivation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Invest Dermatol. 2006 Dec;126(12):2727-9; author reply 2729-30 [16874313.001]
  • (PMID = 16410785.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Taylor SF, Cook AE, Leatherbarrow B: Review of patients with basal cell nevus syndrome. Ophthal Plast Reconstr Surg; 2006 Jul-Aug;22(4):259-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of patients with basal cell nevus syndrome.
  • PURPOSE: To review patients with basal cell nevus syndrome (BCNS), documenting presentation, referrals, treatment patterns, and associated morbidity.
  • Demographic data, age at presentation, age at diagnosis, spectrum of ophthalmic and periocular disease, treatment modalities used, and periocular deformities developed were reviewed.
  • Presenting clinical features included odontogenic keratocyst in 17 patients and basal cell carcinoma in 13 patients; less common presentations were with congenital malformations (n = 2), with ophthalmic associations (n = 3), and at genetic counseling (n = 4).
  • Basal cell carcinoma developed in 18 of the 28 patients before the age of 30, confirming the reported early age of onset.
  • Periocular basal cell carcinoma was reported in 24 of 39 patients (61%), with recurrent disease reported in 17 of these 24 (71%), despite a variety of treatment modalities used.
  • CONCLUSIONS: Patients with BCNS frequently have ophthalmic manifestations, particularly periocular basal cell carcinoma.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Basal Cell / pathology. Child. Child, Preschool. Cross-Sectional Studies. Eye Diseases / diagnosis. Eyelid Neoplasms / pathology. Female. Genetic Counseling. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855496.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Saetta AA, Stamatelli A, Karlou M, Michalopoulos NV, Patsouris E, Aroni K: Mutations of microsatellite instability target genes in sporadic basal cell carcinomas. Pathol Res Pract; 2007;203(12):849-55
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of microsatellite instability target genes in sporadic basal cell carcinomas.
  • The aim of our study was to investigate the prevalence of mutations in the above 4 MSI target genes in correlation with the MSI status of 75 basal cell carcinomas (BCCs), including aggressive-growth BCCs and cases with perineural invasion.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. DNA-Binding Proteins / metabolism. Frameshift Mutation. Microsatellite Instability. Protein-Serine-Threonine Kinases / genetics. Receptors, Transforming Growth Factor beta / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Humans. Male. Polymorphism, Single-Stranded Conformational

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950544.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MSH3 protein, human; 0 / Receptors, Transforming Growth Factor beta; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


46. Tachi N, Fujii K, Kimura M, Seki K, Hirakai M, Miyashita T: New mutation of the PTCH gene in nevoid basal-cell carcinoma syndrome with West syndrome. Pediatr Neurol; 2007 Nov;37(5):363-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New mutation of the PTCH gene in nevoid basal-cell carcinoma syndrome with West syndrome.
  • Neurologic involvement in nevoid basal-cell carcinoma syndrome includes intracranial calcification, congenital hydrocephalus, intracranial neoplasms, and mental retardation.
  • A few cases of epilepsy with nevoid basal-cell carcinoma syndrome were reported.
  • We report on a patient with nevoid basal-cell carcinoma syndrome and West syndrome.
  • This mutation was not found in previously described patients with nevoid basal-cell carcinoma syndrome.
  • [MeSH-major] Basal Cell Nevus Syndrome / genetics. Brain Neoplasms / genetics. Mutation / genetics. Receptors, Cell Surface / genetics. Spasms, Infantile / genetics

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • Genetic Alliance. consumer health - West syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950424.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


47. Nazari Z, Omranipour R: Unusual location of vulvar basal cell carcinoma. J Low Genit Tract Dis; 2006 Oct;10(4):242-4
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual location of vulvar basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) is a rare tumor of the vulva; it accounts for approximately 2% to 4% of vulvar cancer.
  • She underwent wide local excision of tumor without any damage to the anal sphincter.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Perineum / pathology. Vulvar Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17012990.001).
  • [ISSN] 1089-2591
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Chai L, Tang J: [Analysis of 41 cases of basal cell carcinoma in maxillofacial area]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Apr;20(7):297-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 41 cases of basal cell carcinoma in maxillofacial area].
  • OBJECTIVE: To explore the incidence, location and relationship between surgical margin and metastasis of basal cell carcinoma (BCC) in maxillofacial area.
  • In patients who received operation, the difference of the positive rates between 0.3 cm and 0.5 cm of surgical margin of the T1 stage tumor was significant (P<0.05).
  • [MeSH-major] Carcinoma, Basal Cell. Facial Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780141.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Nikkels AF, Piérard-Franchimont C, Nikkels-Tassoudji N, Bourguignon R, Piérard GE: Photodynamic therapy and imiquimod immunotherapy for basal cell carcinomas. Acta Clin Belg; 2005 Sep-Oct;60(5):227-34
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy and imiquimod immunotherapy for basal cell carcinomas.
  • Photodynamic therapy (PDT) and topical imiquimod immunotherapy (TII) are two recently introduced treatment modalities for certain types of basal cell carcinomas (BCC).
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398319.001).
  • [ISSN] 1784-3286
  • [Journal-full-title] Acta clinica Belgica
  • [ISO-abbreviation] Acta Clin Belg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; 99011-02-6 / imiquimod
  •  go-up   go-down


50. Schulte KW, Lippold A, Auras C, Bramkamp G, Breitkopf C, Elsmann HJ, Habenicht EM, Jasnoch V, Müller-Pannes H, Rupprecht R, Suter L: Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas. J Am Acad Dermatol; 2005 Dec;53(6):993-1001
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas.
  • BACKGROUND: We have used a schedule for soft x-ray therapy of epithelial malignancies that takes into account the clinically diagnosed tumor involution under treatment.
  • METHODS: Patients with 1267 consecutively irradiated (1988-1992) basal cell and squamous cell carcinomas were followed up (average 77 months).
  • RESULTS: The recurrence rate (5.1%) was related to tumor size and thickness and to the time-dose-fractionation factor.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy Dosage. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310060.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Xie J: Molecular biology of basal and squamous cell carcinomas. Adv Exp Med Biol; 2008;624:241-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of basal and squamous cell carcinomas.
  • Basal cell carcinomas and Squamous cell carcinomas are the two most common human cancers.
  • For example, identification of hedgehog signaling activation has opened up many opportunities for targeted therapy and prevention of basal cell carcinomas.
  • Significant progress has also been made in our understanding of squamous cell carcinomas of the skin.
  • In this chapter, we will focus on major recent developments in our understanding of basal cell carcinomas and squamous cell carcinomas at the molecular levels and their clinical implications.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Molecular Biology. Mutation / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Animals. Chromosome Aberrations. Disease Models, Animal. Humans. Mice

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18348461.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA94160
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 85
  •  go-up   go-down


52. Fresini A, Rossiello L, Severino BU, Del Prete M, Satriano RA: Giant basal cell carcinoma. Skinmed; 2007 Jul-Aug;6(4):204-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma.
  • A 72-year-old white man presented with a large cutaneous tumor on his back.
  • The tumor mostly showed an adenoid pattern: gland-like structures and cystic spaces sometimes containing amorphous or granular material, surrounded by strands of basaloid cells devoid of any peripheral palisading (Figure 2C).
  • Therefore, a diagnosis of basal cell carcinoma, adenoid subtype, was made.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618177.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Hutcheson AC, Fisher AH, Lang PG Jr: Basal cell carcinomas with unusual histologic patterns. J Am Acad Dermatol; 2005 Nov;53(5):833-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinomas with unusual histologic patterns.
  • Uncommon histologic variants of basal cell carcinoma (BCC) can present a diagnostic challenge.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243134.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Chadha V, Wright M: Small margin excision of periocular basal cell carcinomas. Br J Ophthalmol; 2009 Jun;93(6):803-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small margin excision of periocular basal cell carcinomas.
  • AIMS: To analyse the outcome of small margin (up to 2 mm) excision of primary clinically well-defined periocular basal cell carcinomas (BCCs).
  • All patients underwent excision of the tumour with maximum margins of 2 mm.
  • In the absence of availability of Mohs surgery, well-demarcated nodular basal cell carcinomas can be safely excised using smaller margins than conventionally practised.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Ophthalmol. 2010 Aug;94(8):1114 [20530178.001]
  • (PMID = 19304655.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. van der Geer S, Ostertag JU, Krekels GA: Treatment of basal cell carcinomas in patients with nevoid basal cell carcinoma syndrome. J Eur Acad Dermatol Venereol; 2009 Mar;23(3):308-13
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of basal cell carcinomas in patients with nevoid basal cell carcinoma syndrome.
  • BACKGROUND: Nevoid basal cell carcinoma syndrome (NBCCS) is characterized by the development of multiple basal cell carcinomas (BCCs).
  • [MeSH-major] Basal Cell Nevus Syndrome / therapy. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207641.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aminoquinolines; 99011-02-6 / imiquimod
  • [Number-of-references] 51
  •  go-up   go-down


56. Nseir A, Estève E: [Basal cell carcinoma]. Presse Med; 2008 Oct;37(10):1466-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell carcinoma].
  • [Transliterated title] Carcinomes basocellulaires.
  • Basal cell carcinoma (BCC) accounts for 80% of skin cancers, and its frequency is increasing substantially and regularly.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18687568.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 17
  •  go-up   go-down


57. Huang SW, Liu KT, Chang CC, Chen YJ, Wu CY, Tsai JJ, Lu WC, Wang YT, Liu CM, Shieh JJ: Imiquimod simultaneously induces autophagy and apoptosis in human basal cell carcinoma cells. Br J Dermatol; 2010 Aug;163(2):310-20
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod simultaneously induces autophagy and apoptosis in human basal cell carcinoma cells.
  • BACKGROUND: Imiquimod shows antitumour activity through the stimulation of cell-mediated immunity in vivo.
  • Recent studies have shown that imiquimod promotes apoptosis in melanoma cells and induces autophagy in macrophage cell lines.
  • OBJECTIVES: To evaluate the imiquimod-induced apoptosis, autophagy and their relationship in a basal cell carcinoma (BCC) cell line.
  • METHODS: Cell viability was determined by XTT test.
  • Both apoptosis and autophagy induced by imiquimod cooperate to cause BCC cell death.
  • However, inhibition of imiquimod-induced apoptosis increased the strength of autophagy, and inhibition of imiquimod-induced autophagy further promoted cell apoptosis.
  • CONCLUSIONS: This study not only demonstrates that imiquimod can directly induce autophagy and apoptosis in BCC cells, but also shows the cooperation and coordination between these two processes to induce cell death.
  • [MeSH-major] Aminoquinolines / pharmacology. Antineoplastic Agents / pharmacology. Apoptosis. Autophagy. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Caspase Inhibitors. Caspases / metabolism. Cell Line, Tumor / drug effects. Dose-Response Relationship, Drug. Humans. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426785.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Caspase Inhibitors; 99011-02-6 / imiquimod; EC 3.4.22.- / Caspases
  •  go-up   go-down


58. Fernandez-Flores A: Advanced differentiation in trichoepithelioma and basal cell carcinoma investigated by immunohistochemistry against neurofilaments. Folia Histochem Cytobiol; 2009;47(1):61-4
MedlinePlus Health Information. consumer health - Hair Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced differentiation in trichoepithelioma and basal cell carcinoma investigated by immunohistochemistry against neurofilaments.
  • Basal cell carcinoma (BCC) and trichoepithelioma (TE) are sometimes diagnostic challenges for the pathologist in terms of their differential diagnosis.
  • Although literature is quite rich in information about histologic and immunohistochemical clues to distinguish the differences between both, no single finding must be completely reliable.
  • Moreover, some consider that TE is a better differentiated follicular tumour, while BCC represents a less developed stage in differentiation.
  • Since this plexus is a late sign of differentiation and since both types of neoplasias share it, we conclude that TE and BCC are both terminally differentiated neoplasms.
  • The ability of BCC to infiltrate would have more to do with the acquisition by the tumour of such a property, rather than with a stage of indifferentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19419939.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


59. Sahin B, Ozdemir R, Kocer U, Cologlu H, Kayiran O, Oruc M: Multi-centric basal and squamous cell skin malignancies of the craniofacial region. J Craniofac Surg; 2006 Mar;17(2):265-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-centric basal and squamous cell skin malignancies of the craniofacial region.
  • Of the 98 malignancies, 24 were squamous cell cancer, 67 were basal cell cancer, and seven were basosquamous cell cancer pathologically.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Head and Neck Neoplasms / etiology. Skin Neoplasms / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Disease Susceptibility. Female. Humans. Male. Middle Aged. Risk Factors. Skin Transplantation. Sunlight / adverse effects. Surgical Flaps. Xeroderma Pigmentosum / complications

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633173.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Schwartzberg JB, Elgart GW, Romanelli P, Fangchao M, Federman DG, Kirsner RS: Accuracy and predictors of basal cell carcinoma diagnosis. Dermatol Surg; 2005 May;31(5):534-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy and predictors of basal cell carcinoma diagnosis.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common cancer in the United States.
  • We also sought to determine which clinical and historical factors most influence a dermatologist's perception that a tumor is a BCC and to determine which factors are correlated with a lesion being a BCC.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Dermatology / standards. Practice Patterns, Physicians' / standards. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962736.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Kanitakis J, Chouvet B: Granular-cell basal cell carcinoma of the skin. Eur J Dermatol; 2005 Jul-Aug;15(4):301-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular-cell basal cell carcinoma of the skin.
  • Granular cell basal cell carcinoma (GBCC) is a very rare variant of BCC, of which ten cases have been reported in the literature.
  • The tumor developed on the face of a 71-year old man and showed typical features of GBCC, i.e. a tumor reminiscent of nodular BCC consisting of cells with a granular eosinophilic cytoplasm.
  • Immunohistochemically, tumor cells expressed cytoplasmic reactivity for keratins, CD68 and CD15 antigens, bcl-2 oncoprotein and nuclear reactivity for the p63 protein.
  • [MeSH-major] Adenocarcinoma / diagnosis. Skin Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048765.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 12
  •  go-up   go-down


62. Saglam O, Salama M, Meier F, Chaffins M, Ma C, Ormsby A, Lee M: Immunohistochemical staining of palisading basal cells in Bowen's disease and basal involvement in actinic keratosis: contrasting staining patterns suggest different cells of origin. Am J Dermatopathol; 2008 Apr;30(2):123-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining of palisading basal cells in Bowen's disease and basal involvement in actinic keratosis: contrasting staining patterns suggest different cells of origin.
  • Actinic keratosis (AK) and Bowen's disease (BD) are common patterns of in situ squamous cell carcinoma of the epidermis.
  • In AK, atypical keratinocytes proliferate in the lower portion of the epidermis including the basal layer.
  • In contrast, BD features atypical squamous cells in all portions of the epidermis but initially leaves basal cells in palisades along the basement membrane.
  • To characterize immunohistochemically keratocyte proliferation in AK and Palisading Basal Cells (PBC) in BD, we stained microarray samples of 45 AK and 25 BD with Molecular Immunology Borstel (MIB-1).
  • Subsequent immunostaining of full mounted sections examined 11 BD, 7 AK, and 4 examples of psoriasis for MIB-1 (as a proliferative marker) and p53 (as a cell cycle regulatory marker).
  • AK stained for MIB-1 and p53 antibodies only in lower portion of epidermis and included the basal layer.
  • BD with typical PBCs stained positive for both markers throughout the epidermis, except for the basal layer.
  • Psoriatic biopsies stained positively for the 2 markers only in the basal and parabasal layers.
  • Normal epidermis adjacent to the lesions in AK and BD biopsies stained sparsely in the basal layers.
  • Lack of expression of proliferative antigens in palisading basal cells in BD provides evidence that PBCs are not the cell of origin for BD.
  • Conversely in AK, expression of MIB-1 and p53 in basal cells argues that these cells play a role in histogenesis of AK.
  • [MeSH-major] Bowen's Disease / pathology. Carcinoma, Basal Cell / pathology. Keratosis / pathology. Ki-67 Antigen / metabolism. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biopsy, Needle. Cohort Studies. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Immunohistochemistry. Male. Middle Aged. Sensitivity and Specificity. Staining and Labeling / methods

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360114.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


63. Oldfield V, Keating GM, Perry CM: Imiquimod: in superficial basal cell carcinoma. Am J Clin Dermatol; 2005;6(3):195-200; discussion 201-2
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod: in superficial basal cell carcinoma.
  • Imiquimod, available as a 5% cream, is a new topical treatment for adults with superficial basal cell carcinoma (BCC).
  • Imiquimod may act as a toll-like receptor-7 agonist, and is thought to exert its anti-tumor effect via modification of the immune response and stimulation of apoptosis in BCC cells.
  • [MeSH-major] Aminoquinolines / pharmacology. Aminoquinolines / therapeutic use. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943496.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  • [Number-of-references] 23
  •  go-up   go-down


64. Asplund A, Sivertsson A, Bäckvall H, Ahmadian A, Lundeberg J, Ponten F: Genetic mosaicism in basal cell carcinoma. Exp Dermatol; 2005 Aug;14(8):593-600
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic mosaicism in basal cell carcinoma.
  • Human basal cell cancer (BCC) shows unique growth characteristics, including a virtual inability to metastasize, absence of a precursor stage and lack of tumour progression.
  • The clonal nature of BCC has long been a subject for debate because of the tumour growth pattern.
  • Four parts of each individual tumour plus isolated samples of stroma were analysed following laser-assisted microdissection.
  • In 12/13 tumours, the epithelial component of the tumour showed a monoclonal pattern suggesting a unicellular origin.
  • Surprisingly, one tumour showed evidence of being composed of at least two non-related monoclonal clones.
  • This finding was supported by the analysis of the ptch and p53 gene.
  • Clonality analysis of tumour stroma showed both mono- and polyclonal patterns.
  • The study results show that what appears to be one tumour may occasionally constitute two or more independent tumours intermingled or adjacent to each other, possibly reflecting a local predisposition to malignant transformation.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Cell Transformation, Neoplastic. Mosaicism. Neoplasms, Glandular and Epithelial / genetics. Receptors, Androgen / genetics
  • [MeSH-minor] Chromosome Aberrations. Chromosomes, Human, X. DNA / metabolism. Disease Progression. Dosage Compensation, Genetic. Epidermis / metabolism. Epithelium / metabolism. Female. Heterozygote. Humans. Lasers. Loss of Heterozygosity. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026581.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 109400
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Receptors, Androgen; 0 / Tumor Suppressor Protein p53; 9007-49-2 / DNA
  •  go-up   go-down


65. Fukunaga M: Cutaneous spindle cell carcinoma following basal cell carcinoma. Am J Dermatopathol; 2005 Feb;27(1):17-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous spindle cell carcinoma following basal cell carcinoma.
  • A spindle cell carcinoma arose three years after the seeming excision of a so-called "infiltrative" basal cell carcinoma (IBCC) in the cheek of an 87-year-old Japanese woman.
  • The tumor was composed of short fascicles and whorling arrangements of spindle to polygonal cells without residual IBCC.
  • Immunohistochemically, the tumor was positive for vimentin, cytokeratin 8 & 18, epithelial membrane antigen, and alpha-smooth muscle actin.
  • Ultrastructurally, the tumor cells had tonofilaments and desmosomes.
  • This case and others support the concept that spindle cell carcinoma can pursue an aggressive clinical course.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Basal Cell / pathology. Neoplasms, Second Primary. Skin Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Fatal Outcome. Female. Humans. Keratins / analysis. Mucin-1 / analysis. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2005 Dec;27(6):546; author reply 546 [16314711.001]
  • (PMID = 15677971.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


66. Tévar E, Torrelo A, Contreras F, Colmenero I, Zambrano A: [Multiple basal cell carcinomas on phacomatosis pigmentokeratotica]. Actas Dermosifiliogr; 2006 Oct;97(8):518-21
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple basal cell carcinomas on phacomatosis pigmentokeratotica].
  • [Transliterated title] Carcinomas basocelulares múltiples sobre facomatosis pigmentoqueratótica.
  • We present a patient with phacomatosis pigmentokeratotica (PPK) who developed several basal cell carcinomas on epidermal nevus lesions in adult life.
  • PPK shows an elevated incidence of development of malignant lesions both on the sebaceous or epidermal nevus component as well as on the nevus spilus one.
  • [MeSH-major] Carcinoma, Basal Cell. Neoplasms, Multiple Primary. Neurocutaneous Syndromes. Skin Neoplasms

  • Genetic Alliance. consumer health - Phacomatosis pigmentokeratotica.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067530.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


67. Taherian K, Shekarchian M, Atkinson PL: Surgical excision of periocular basal cell carcinomas. Indian J Ophthalmol; 2007 Mar-Apr;55(2):137-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision of periocular basal cell carcinomas.
  • The purpose of this study was to determine the histological clearance and clinical recurrence rates following excision of primary periocular biopsy-proven basal cell carcinomas (BCCs) in a teaching hospital in United Kingdom and compare it with other published reports.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Ophthalmologic Surgical Procedures / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. England / epidemiology. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17322605.001).
  • [ISSN] 0301-4738
  • [Journal-full-title] Indian journal of ophthalmology
  • [ISO-abbreviation] Indian J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


68. High A, Zedan W: Basal cell nevus syndrome. Curr Opin Oncol; 2005 Mar;17(2):160-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell nevus syndrome.
  • PURPOSE OF REVIEW: Basal cell nevus syndrome (BCNS), is a hereditary condition transmitted as an autosomal dominant trait exhibiting high penetrance and variable expressivity.
  • Inherited or spontaneous mutations in the human homologue of the Drosophila patched gene underlie the disorder and in addition to tumor predisposition, are associated with a range of 'patterning' defects.
  • These developmental abnormalities occur as a result of haplo-insufficiency in heterozygotes for the mutated gene, whereas neoplastic complications arise from a classical two-hit tumor suppressor gene model.
  • [MeSH-major] Basal Cell Nevus Syndrome / etiology. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Nevus.
  • Genetics Home Reference. consumer health - Gorlin syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725922.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins
  • [Number-of-references] 59
  •  go-up   go-down


69. Newman JC, Leffell DJ: Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma. Dermatol Surg; 2007 Aug;33(8):957-64; discussion 965
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma.
  • BACKGROUND: The clinical relevance of the anatomic distribution of basal cell carcinoma is not completely understood.
  • Embryonic fusion planes--the regions of mesenchymal migration and fusion of the five primordial facial processes during the 5th to 10th weeks of human development--have been implicated in the pathogenesis of basal cell carcinoma.
  • OBJECTIVE: This study sought to examine the predilection of midfacial basal cell carcinoma for cutaneous anatomical sites correlated to embryonic fusion planes.
  • METHODS AND MATERIALS: Using archived digital images and a detailed anatomic diagram, cases of basal cell carcinoma were coded according to their specific location and were aggregated into two anatomic domains according to their correlation to embryonic fusion planes.
  • The relative tumor densities were calculated.
  • The relative tumor density of lesions in the fusion plane domain was 3.06 compared to 0.74 for the remaining lesions (p< .001).
  • CONCLUSIONS: Although there is no consensus about the importance of anatomic location in the pathogenesis of basal cell carcinoma, these data indicate that, after adjusting for surface area, basal cell carcinoma was more than four times more likely to occur on an embryonic fusion plane than on other regions of the midface.
  • These data support the possibility of an embryologic role for the pathogenesis of basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / embryology. Carcinoma, Basal Cell / pathology. Facial Neoplasms / embryology. Facial Neoplasms / pathology. Skin Neoplasms / embryology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2008 Jun;34(6):851-3; author reply 853 [18384370.001]
  • (PMID = 17661939.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL: Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med; 2006 Nov;12(11):537-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deconstructing the molecular portrait of basal-like breast cancer.
  • Basal-like tumors are a newly recognized subtype of breast cancer, which express genes that are characteristic of basal epithelial cells, such as the basal cytokeratins, and are associated with poor relapse-free and overall survival.
  • Here, we focus on new insights into the molecular pathogenesis of basal-like breast cancer and explore how these discoveries might impact the treatment of these poor-prognosis tumors.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011236.001).
  • [ISSN] 1471-4914
  • [Journal-full-title] Trends in molecular medicine
  • [ISO-abbreviation] Trends Mol Med
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / T32 GM008152; United States / NCI NIH HHS / CA / P50 CA 89018; United States / NCI NIH HHS / CA / R01 CA 097198
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / Biomarkers, Tumor; 0 / beta-Crystallin A Chain; EC 2.7.10.1 / Receptor, ErbB-2
  • [Number-of-references] 80
  •  go-up   go-down


71. Takenouchi T: [Basal cell carcinoma]. Gan To Kagaku Ryoho; 2006 Oct;33(10):1398-403
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell carcinoma].
  • Basal cell carcinoma (BCC) is the most common skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033227.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 99011-02-6 / imiquimod
  • [Number-of-references] 37
  •  go-up   go-down


72. Levy J, Cagnano E, Benharroch D, Monos T, Lifshitz T: Collision sebaceous and basal cell carcinomas of the eyelid. Ann Diagn Pathol; 2006 Jun;10(3):157-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision sebaceous and basal cell carcinomas of the eyelid.
  • OBJECTIVE: To report a rare case of collision sebaceous and basal cell carcinomas of the eyelid.
  • Histopathology showed mixed sebaceous as well as basal cell carcinoma with uninvolved surgical margins.
  • CONCLUSION: Sebaceous and basal cell carcinomas can coexist in the eyelid within the same clinical lesion.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730311.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


73. Veenstra-Knol HE, Scheewe JH, van der Vlist GJ, van Doorn ME, Ausems MG: Early recognition of basal cell naevus syndrome. Eur J Pediatr; 2005 Mar;164(3):126-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early recognition of basal cell naevus syndrome.
  • The basal cell naevus syndrome is an autosomal dominant syndrome characterised by major manifestations such as basal cell carcinomas, jaw cysts, palmar or plantar pits, and intracranial calcifications.
  • We describe three unrelated children with basal cell naevus syndrome who appeared to be the first patient in each family.
  • CONCLUSION: Our observations lead us to recommend looking for other manifestations of this disease in patients who present with cardiac fibroma, cleft lip/palate, polydactyly or macrocephaly.
  • [MeSH-major] Basal Cell Nevus Syndrome / diagnosis
  • [MeSH-minor] Child. Child, Preschool. Craniofacial Abnormalities / genetics. Female. Fibroma / genetics. Heart Neoplasms / genetics. Humans. Infant. Male. Mutation. Patched Receptors. Polydactyly / genetics. Pupil Disorders / genetics. Receptors, Cell Surface / genetics. Ribs / abnormalities

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Pediatr. 2005 Mar;164(3):123-5 [15717175.001]
  • [Cites] Am Fam Physician. 2002 Jun 15;65(12):2501-4 [12086239.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] J Invest Dermatol. 2003 Sep;121(3):478-81 [12925203.001]
  • [Cites] Am J Med Genet. 1997 Dec 19;73(3):304-7 [9415689.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] Am J Med Genet. 1994 Apr 15;50(3):282-90 [8042673.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Mar;33(2):117-24 [15050066.001]
  • [Cites] J Med Genet. 1993 Jun;30(6):460-4 [8326488.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10 (7):757-62 [11257109.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):113-25 [7712637.001]
  • (PMID = 15717176.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Patched Receptors; 0 / Receptors, Cell Surface
  •  go-up   go-down


74. Chuprov IN: [Immunomorphological features of cutaneous basal-cell carcinoma]. Vopr Onkol; 2008;54(6):715-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunomorphological features of cutaneous basal-cell carcinoma].
  • An immunohistochemical study of p53, Ki-67, bcl-2, CK-8 and collagen IV was conducted in 47 basal-cell carcinomas (BCC) to ascertain their prognostic value.
  • CK-8 expression did not vary significantly within the 67.21-71.39% of tumor cells as far as different histotopographic patterns are concerned.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / pathology. Skin Neoplasms / chemistry. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Basement Membrane / chemistry. Basement Membrane / pathology. Collagen Type IV / analysis. Female. Humans. Immunohistochemistry. Keratin-8 / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Invasiveness. Proto-Oncogene Proteins c-bcl-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241845.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type IV; 0 / Keratin-8; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


75. Wiedemeyer K, Hartschuh W: Trichoblastomas with Merkel cell proliferation in nevi sebacei in Schimmelpenning-Feuerstein-Mims syndrome--histological differentiation between trichoblastomas and basal cell carcinomas. J Dtsch Dermatol Ges; 2009 Jul;7(7):612-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trichoblastomas with Merkel cell proliferation in nevi sebacei in Schimmelpenning-Feuerstein-Mims syndrome--histological differentiation between trichoblastomas and basal cell carcinomas.
  • Nevi sebacei can proliferate and develop into epithelial tumors like trichoblastoma, syringocystadenoma and basal cell carcinoma.
  • The histological differentiation between basal cell carcinoma and trichoblastoma is difficult.
  • She was referred to us with the diagnosis of multiple basal cell carcinomas of head and face.
  • We identified multiple trichoblastomas in the nevi sebacei and could exclude basal cell carcinomas.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Merkel Cells / pathology. Nevus, Sebaceous of Jadassohn / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / pathology. Cell Proliferation. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19192012.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


76. Konstantinović VS, Lazić VM, Stefan I: Nasal epithesis retained by basal (disk) implants. J Craniofac Surg; 2010 Jan;21(1):33-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal epithesis retained by basal (disk) implants.
  • AIM: To report the case of a patient who underwent facial reconstruction with nasal epithesis anchored on basal (disk) implants after ablation of midface squamous cell carcinoma.
  • METHODS: Ablative surgery of the midface region and insertion of 3 basal implants into the glabellar area of the frontal bone, the upper part of the right side of the alveolar crest, and the lateral side of the maxillary bone, which forms the left lateral wall of the nose, respectively, was performed.
  • At the control examinations after 1, 3, 6, 12, and 18 months, respectively, there were no signs of recurrence of the tumor or any complications related to the implants.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Facial Bones / surgery. Facial Neoplasms / surgery. Nose Neoplasms / surgery. Prostheses and Implants. Skull Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061980.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Karagas MR, Nelson HH, Sehr P, Waterboer T, Stukel TA, Andrew A, Green AC, Bavinck JN, Perry A, Spencer S, Rees JR, Mott LA, Pawlita M: Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst; 2006 Mar 15;98(6):389-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin.
  • BACKGROUND: Although infection with human papillomaviruses (HPVs) is a major risk factor for several epithelial cancers, an etiologic relationship between HPV and keratinocyte cancers, such as squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs), remains unclear.
  • [MeSH-major] Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / virology. Papillomaviridae. Papillomavirus Infections / complications. Skin Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2006 Oct 4;98(19):1425-6 [17018790.001]
  • (PMID = 16537831.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA57494
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Bechert CJ, Stern JB: Basal cell carcinoma with perineural invasion: reexcision perineural invasion? J Cutan Pathol; 2010 Mar;37(3):376-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with perineural invasion: reexcision perineural invasion?
  • BACKGROUND: Perineural invasion (PI) in basal cell and squamous cell carcinomas, especially of the head and neck, has been reported to indicate an increased morbidity.
  • Reexcision perineural invasion (RPI), a benign mimic of tumoral perineural invasion, may present a difficult histologic differential diagnosis.
  • METHODS: We surveyed the medical literature for PI occurring in basal cell carcinomas to investigate the degree to which the reported cases occurred in reexcision specimens vs. primary biopsy specimens.
  • RESULTS: We found large retrospective studies of 14,120 basal cell carcinomas evaluated for PI in which 310 cases of PI were identified (2.2%), and 20 sporadic case reports of basal cell carcinomas with PI.
  • Of 310 cases of basal cell carcinoma with PI, 196 (63%) were in reexcision specimens.
  • CONCLUSION: The high percentage of PI occurring in reexcision specimens vs. primary excisions may indicate that many of the reported cases of basal cell carcinomas with PI are actually examples of RPI.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Invasiveness / pathology. Neoplasm Seeding. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Reoperation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2011 Jan;38(1):76-7 [20840330.001]
  • [CommentIn] J Cutan Pathol. 2012 Nov;39(11):1047-8 [22830947.001]
  • [CommentIn] J Cutan Pathol. 2011 Jan;38(1):78-9 [20860728.001]
  • (PMID = 19615028.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


79. Uzquiano MC, Prieto VG, Nash JW, Ivan DS, Gong Y, Lazar AJ, Diwan AH: Metastatic basal cell carcinoma exhibits reduced actin expression. Mod Pathol; 2008 May;21(5):540-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma exhibits reduced actin expression.
  • Basal cell carcinoma is the most common malignancy in Caucasian individuals.
  • Metastatic basal cell carcinoma is extremely rare (with a rate estimated as 0.03%).
  • Actin has been detected in aggressive forms of basal cell carcinoma, but their expression in metastatic lesions is not known.
  • We compared the expression of actin and actin-related cytoskeletal proteins in relatively less aggressive basal cell carcinoma (nodular), aggressive basal cell carcinoma (infiltrative/morpheaform), and metastatic basal cell carcinoma.
  • We studied 12 cases of nodular basal cell carcinoma, 10 cases of infiltrative basal cell carcinoma, and 10 cases of metastatic basal cell carcinoma with immunohistochemistry for alpha-smooth muscle actin, calponin, myosin, and E-cadherin.
  • Expression was interpreted as positive when at least 5% of the tumor exhibited at least weak expression.
  • Five of the ten patients with metastatic basal cell carcinoma had an antecedent history of radiotherapy.
  • Actin was present in 3 of 12 (25%) of the nodular, all 10 of the infiltrative, and 3 of 10 of the metastatic basal cell carcinomas (P<0.05 for metastatic vs infiltrative and nodular vs infiltrative).
  • Calponin was present in 50% of the nodular, 60% of the infiltrative, and 30% of the metastatic basal cell carcinomas (not statistically significant).
  • E-cadherin was present in 75% of the nodular, 70% of the infiltrative, and all of the metastatic basal cell carcinomas (P<0.05 for metastatic vs nodular).
  • [MeSH-major] Actins / biosynthesis. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Neoplasm Invasiveness. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223552.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Cadherins; 0 / Calcium-Binding Proteins; 0 / Microfilament Proteins; 0 / calponin; EC 3.6.4.1 / Myosins
  •  go-up   go-down


80. Kovarik CL, Stewart D, Barnard JJ: Lethal basal cell carcinoma secondary to cerebral invasion. J Am Acad Dermatol; 2005 Jan;52(1):149-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lethal basal cell carcinoma secondary to cerebral invasion.
  • Intracranial invasion by a basal cell carcinoma on the scalp is extremely rare.
  • We present an autopsy case of a 57-year-old woman who developed a large destructive basal cell carcinoma with extension through the calvarium and compression of the dura.
  • We compare 7 similar cases reported in the literature and review the risks for development of these aggressive fatal basal cell carcinomas on the scalp.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Scalp. Skin Neoplasms / pathology
  • [MeSH-minor] Autopsy. Female. Humans. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15627099.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


81. Kiyici H, Bilezikçi B, Ozen O, Demirhan B: Immunohistochemical FHIT expression still exists in early lesions of basal cell carcinoma. Pathol Res Pract; 2010 Jul 15;206(7):445-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical FHIT expression still exists in early lesions of basal cell carcinoma.
  • In this study, we evaluated the expression of Fragile Histidine Triad (FHIT) in basal cell carcinoma (BCC).
  • As a second finding, there was no correlation between the intensity of FHIT staining and Ki-67 labeling index.
  • As a third finding, there was no difference in Ki-67 labeling index between early lesions of BCC and non-neoplastic epidermis.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Carcinoma, Basal Cell / metabolism. Neoplasm Proteins / biosynthesis. Skin Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20399571.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


82. Kawata R, Yoshimura K, Lee K, Araki M, Takenaka H, Tsuji M: Basal cell adenoma of the parotid gland: a clinicopathological study of nine cases--basal cell adenoma versus pleomorphic adenoma and Warthin's tumor. Eur Arch Otorhinolaryngol; 2010 May;267(5):779-83
Genetic Alliance. consumer health - Warthin's tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland: a clinicopathological study of nine cases--basal cell adenoma versus pleomorphic adenoma and Warthin's tumor.
  • The aim of this study is to investigate the clinical and pathological characteristics of basal cell adenoma (BCA) and to compare the diagnosis/treatment of BCA with those of Warthin's tumor (WT) and pleomorphic adenoma (PA).
  • Among 192 patients with benign tumors of the parotid gland who underwent surgery, 9 had BCA.
  • All of these tumors showed a benign pattern on computed tomography and magnetic resonance imaging.
  • Considering the gender difference, tumor site, and age, it is necessary to differentiate BCA from PA rather than from WT.
  • BCA is the third most common of the benign parotid tumors, following WT and PA, although its incidence is low.
  • When PA and WT are ruled out by FNAB after a tentative diagnosis of benign tumor has been based on imaging findings, BCA should be considered.
  • [MeSH-major] Adenolymphoma / pathology. Adenoma / pathology. Adenoma, Pleomorphic / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 2007 Feb;35(2):85-90 [17230571.001]
  • [Cites] Acta Otolaryngol. 1998 Jul;118(4):588-93 [9726688.001]
  • [Cites] Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1967;189(3):302-16 [5595712.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):260-4 [15468947.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):736-45 [6284339.001]
  • [Cites] Br J Radiol. 2005 Jul;78(931):642-5 [15961849.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar 01;11(2):E206-9 [16505803.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):439-47 [9452259.001]
  • (PMID = 19908055.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Asuman C, Ozlem A, Burçak T, Onder P: An unusual location of basal cell carcinoma: the clitoris and the vulva. Indian J Dermatol; 2008;53(4):192-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual location of basal cell carcinoma: the clitoris and the vulva.
  • Vulvar basal cell carcinoma (BCC) is rare, accounting for less than 5% of all vulvar neoplasms and less than 1% of all BCCs.
  • The patient underwent wide local excision with clitoral amputation and remained disease free at post-surgical follow-up after 18 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):192-4 [15790457.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):172-6 [10102347.001]
  • [Cites] Gynecol Oncol. 2002 Jun;85(3):532-7 [12051887.001]
  • [Cites] Dermatol Surg. 1997 Mar;23(3):207-9 [9145965.001]
  • [Cites] Obstet Gynecol. 1997 Nov;90(5):765-8 [9351761.001]
  • (PMID = 19882033.001).
  • [ISSN] 1998-3611
  • [Journal-full-title] Indian journal of dermatology
  • [ISO-abbreviation] Indian J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2763753
  • [Keywords] NOTNLM ; Basal cell carcinoma / clitoris / vulva
  •  go-up   go-down


84. De Giorgi V, Salvini C, Chiarugi A, Paglierani M, Maio V, Nicoletti P, Santucci M, Carli P, Massi D: In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma. Int J Dermatol; 2009 Mar;48(3):312-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma.
  • BACKGROUND: Imiquimod use in the treatment of basal cell carcinoma (BCC) has proven to be successful in a large percentage of cases, inducing tumor regression; however, the exact cellular mechanism has not been fully clarified.
  • AIM: To measure the morphological changes in the tumor microenvironment and the markers of apoptosis in skin biopsies from patients with BCC before and after imiquimod treatment.
  • METHODS: In this open label study, skin biopsies obtained from 11 patients with BCC were evaluated before and after imiquimod treatment for: (i) morphological changes in the tumor microenvironment, with specific emphasis on the immunophenotype of inflammatory cells around the tumor; and (ii) markers of apoptosis, including expression of death receptors.
  • An increase in the cytotoxic CD3(+)/CD8(+) T-cell population was also observed.
  • Imiquimod treatment was associated with a marked increased in CD20(+) B cells, and a less pronounced enhancement in cells of monocyte-macrophage origin (CD68(+)) surrounding, or within, the tumor.
  • This finding indicates either that macrophages play a minor role in the imiquimod-induced response, or the recruitment of these cells is related to time and dose.
  • Imiquimod treatment decreased CD1A(+) Langerhans cells in the epidermis and increased the number of CD1A(+) dendritic cells within the tumor aggregates.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261026.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


85. Cheretis C, Angelidou E, Dietrich F, Politi E, Kiaris H, Koutselini H: Prognostic value of computer-assisted morphological and morphometrical analysis for detecting the recurrence tendency of basal cell carcinoma. Med Sci Monit; 2008 May;14(5):MT13-19
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of computer-assisted morphological and morphometrical analysis for detecting the recurrence tendency of basal cell carcinoma.
  • BACKGROUND: Nuclear morphometry may provide useful diagnostic and prognostic information about basal cell carcinomas (BCCs) of the skin.
  • RESULTS: Increased patient age, multiple localization of BCCs at the time of diagnosis, and a low degree of peripheral palisading at the histological sections of BCCs were associated with BCC recurrence and consequently worse disease-free survival (DFS).
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Diagnosis, Computer-Assisted / methods. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Algorithms. Cell Nucleus / metabolism. Female. Humans. Image Processing, Computer-Assisted. Male. Models, Statistical. Prognosis. Recurrence. Software. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443558.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


86. Son KD, Kim TJ, Lee YS, Park GS, Han KT, Lim JS, Kang CS: Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin. J Surg Oncol; 2008 Jun 1;97(7):615-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin.
  • BACKGROUND: This study evaluates several tumor-related markers to examine the expression pattern of markers according to the invasiveness and histopathologic differentiation of squamous cell carcinoma and basal cell carcinoma.
  • METHODS: Ninety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
  • RESULTS: The depth of invasion showed a correlation with CD44v6 expression of tumor cell in both squamous cell carcinoma and basal cell carcinoma (P = 0.009, P = 0.036, respectively) and with the MMP-1 expression of stromal cell in squamous cell carcinoma (P = 0.010).
  • The differentiation of squamous cell carcinoma was correlated with Ki-67 index.
  • The loss of palisading arrangement in basal cell carcinoma was correlated with the MMP-1 expression of stromal cells (P = 0.045).
  • CONCLUSIONS: CD44v6 and MMP-1, expressed in tumor cells and stromal cells respectively, are significant markers associated with the invasiveness of tumors in squamous cell carcinoma and basal cell carcinoma of the skin and that it will be helpful to evaluate the invasiveness by measuring the expression of these markers.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / biosynthesis. Female. Genes, erbB-1. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 3 / biosynthesis. Middle Aged. Neoplasm Invasiveness. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404670.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


87. Chew R: Destruction of the orbit and globe by recurrence of basal cell carcinoma. Optometry; 2007 Jul;78(7):344-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Destruction of the orbit and globe by recurrence of basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common skin malignancy and represents 90% of eyelid malignancies.
  • CASE REPORT: The patient described in this case report had basal cell carcinoma of the upper right lid 4 to 5 years prior to examination.
  • He had extensive surgery to remove the tumor and subsequent skin grafting.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Orbit / pathology. Orbital Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Ophthalmologic Surgical Procedures / methods. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601572.001).
  • [ISSN] 1529-1839
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Kunte C, Konz B: [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin]. Hautarzt; 2007 May;58(5):419-26
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin].
  • The incidence of the most common tumors of the skin, basal cell carcinoma and squamous cell carcinoma, has risen rapidly in recent years.
  • They must be able to develop therapeutic strategies adapted to the tumor and the patient.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Invasiveness. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Prognosis. Radiotherapy, Adjuvant. Skin / pathology. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2001 May;177(5):240-6 [11398609.001]
  • [Cites] Facial Plast Surg. 1997 Apr;13(2):79-82 [9243982.001]
  • [Cites] Hautarzt. 2005 May;56(5):430-40 [15815888.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] J Dermatol Surg Oncol. 1994 May;20(5):350 [8176049.001]
  • [Cites] Recent Results Cancer Res. 2002;160:219-24 [12079216.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):915-9 [9041153.001]
  • [Cites] BMJ. 2004 Sep 25;329(7468):705 [15364703.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):752-7 [10792227.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):218-22 [15202839.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):91-5 [17190625.001]
  • [Cites] Br J Dermatol. 2006 Jun;154(6):1202-3 [16704658.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] Dermatol Surg. 2006 Nov;32(11):1309-21 [17083582.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Sep;20(8):926-30 [16922939.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Mar;4(3):260-2 [16626324.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Jul;17(7):574-8 [1860987.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] Hautarzt. 1975 Dec;26(12):647-50 [1213885.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 May;4(5):441-3 [16686614.001]
  • [Cites] Hautarzt. 1995 Sep;46(9):607-14 [7591764.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):483-6 [12963913.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12 (6):569-72 [12459530.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] Recent Results Cancer Res. 2002;160:240-5 [12079219.001]
  • (PMID = 17443305.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 31
  •  go-up   go-down


89. Lacina L, Smetana K Jr, Dvoránková B, Pytlík R, Kideryová L, Kucerová L, Plzáková Z, Stork J, Gabius HJ, André S: Stromal fibroblasts from basal cell carcinoma affect phenotype of normal keratinocytes. Br J Dermatol; 2007 May;156(5):819-29
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal fibroblasts from basal cell carcinoma affect phenotype of normal keratinocytes.
  • OBJECTIVES: Evaluation of the role of stromal fibroblasts on the phenotype of epithelial cells of basal cell carcinoma (BCC).
  • BCCFs were also grafted to NOD/LtSz-Rag1(null) mice to evaluate their malignant potential.
  • However, a fully malignant phenotype did not develop as these cells did not form tumours in immunodeficient mice.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Keratinocytes / pathology. Skin / pathology. Skin Neoplasms / pathology. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263809.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


90. Chen GS, Yu HS, Lan CC, Chow KC, Lin TY, Kok LF, Lu MP, Liu CH, Wu MT: CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma. Br J Dermatol; 2006 May;154(5):910-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma.
  • BACKGROUND: Chemokines and their receptors, well known for their ability to attract leucocytes, also play important roles for tumour progression.
  • OBJECTIVES: To investigate the possible involvement of chemokine receptors in the pathogenesis of cutaneous basal cell carcinoma (BCC).
  • METHODS: We performed an expression analysis of chemokine receptors using a well-characterized human BCC cell line.
  • Upon the finding of CXCR4 expression by BCC, retroviral transduction of BCC cells with the CXCR4 gene was employed to address its functional significance for BCC in vitro and in vivo.
  • RESULTS: We found expression of the CXC chemokine receptor CXCR4 by a human cell line and a subset of tissue samples from BCC, especially in noduloulcerative and sclerosing types.
  • Moreover, xenograft tumour transplants produced by injection of CXCR4-BCC yielded significant tumour progression in nude mice, whereas additional serial injections of CXCR4-blocking peptides resulted in tumour regression.
  • CONCLUSIONS: CXCR4 expression may play a critical role in tumour progression and angiogenesis of certain subtypes of BCC with more aggressive nature, and functional blockade of CXCR4 could be a potential therapeutic strategy for these tumours.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Cell Transformation, Neoplastic / metabolism. Neovascularization, Pathologic / metabolism. Receptors, CXCR4 / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Apoptosis / radiation effects. Cell Proliferation. Chemokine CXCL12. Chemokines, CXC / physiology. Disease Progression. Female. Humans. Mice. Mice, Nude. Neoplasm Proteins / metabolism. Neoplasm Transplantation. Reverse Transcriptase Polymerase Chain Reaction / methods. Signal Transduction. Transduction, Genetic. Transplantation, Heterologous. Tumor Cells, Cultured. Ultraviolet Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634895.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Neoplasm Proteins; 0 / Receptors, CXCR4
  •  go-up   go-down


91. Leibovitch I, McNab A, Sullivan T, Davis G, Selva D: Orbital invasion by periocular basal cell carcinoma. Ophthalmology; 2005 Apr;112(4):717-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital invasion by periocular basal cell carcinoma.
  • OBJECTIVES: To present a large series of patients with orbital invasion by periocular basal cell carcinoma (BCC).
  • MAIN OUTCOME MEASURES: Patients' demographics, clinical presentation, histologic subtypes, treatment modalities, recurrence rate, and tumor-related death.
  • Only 1 patient (1.6%) died from tumor-related causes.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local. Orbital Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Orbit Evisceration. Peripheral Nervous System Neoplasms / radiotherapy. Peripheral Nervous System Neoplasms / secondary. Peripheral Nervous System Neoplasms / surgery. Radiotherapy. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808267.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


92. Shumaker PR, Lane K, Harford R: Linear unilateral basal cell nevus: a benign follicular hamartoma simulating multiple basal cell carcinomas. Cutis; 2006 Aug;78(2):122-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linear unilateral basal cell nevus: a benign follicular hamartoma simulating multiple basal cell carcinomas.
  • We report a case of linear unilateral basal cell nevus (LBCN) occurring on the left lateral neck and left posterior shoulder of a 23-year-old woman.
  • LBCN is a rare benign follicular hamartoma that must be distinguished from the more aggressive unilateral and segmental variant of nevoid basal cell carcinoma syndrome (NBCCS) and the linear variant of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Hamartoma / pathology. Nevus / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16983901.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Chen RJ, Xiao YQ: [Clinical and pathological analysis of 2734 cases of eyelid neoplasms]. Zhonghua Yan Ke Za Zhi; 2008 Feb;44(2):143-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and pathological analysis of 2734 cases of eyelid neoplasms].
  • OBJECTIVE: To study the histopathological classification and changes of eyelid neoplasms.
  • METHOD: In this retrospective case series, the pathological specimens of 2734 cases with eyelid neoplasms examined between 1993-2005 were claimed and analyzed.
  • RESULTS: There were 1248 eyelid tumors (45.65%) in 2734 cases with eyelid neoplasms, including 875 benign neoplasms (71.11%) and 960 malignant cases (29.89%).
  • The three leading malignant eyelid tumors were basal cell carcinoma, meibomian gland carcinoma and squamous cell carcinoma The mean ages of the occurrence of these three tumors were 64.16, 63.30 and 60.38 years old, respectively.
  • CONCLUSION: Pathologic classification of eyelid neoplasms is helpful for the pathological diagnosis and provides information for the diagnosis and treatment of these diseases.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18683700.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


94. Shemesh S, Spencer JM, Phelps RG: Pattern of development of basal versus squamous cell carcinoma. J Drugs Dermatol; 2006 Jan;5(1):40-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of development of basal versus squamous cell carcinoma.
  • BACKGROUND: Basal cell and squamous cell carcinomas both arise in the epidermis of fair-skinned people in response to ultraviolet light, with the overall frequency of basal cell carcinoma being 4 times that of squamous cell carcinoma.
  • Despite the similarities in the population at risk, and the presumed etiology of these tumors, it is unclear if any one individual has a proclivity to develop only one type of tumor.
  • OBJECTIVE: The study explores whether or not there is a pattern of expression of basal versus squamous cell carcinoma among people with these cancers.
  • METHODS: This case-control study involved patients with a total of more than 3 and fewer than 10 basal or squamous cell carcinomas.
  • Patient age and gender, as well as number and location of diagnosed basal and squamous cell carcinomas were gathered and patterns within these values were sought.
  • RESULTS: Patients found to have at least one basal cell carcinoma tended to produce more basal cell carcinomas and patients found to have at least one squamous cell carcinoma tended to produce more squamous cell carcinomas.
  • CONCLUSION: The study supports the possibility that people who develop basal cell carcinoma are more likely to develop more basal cell carcinomas.
  • Similarly, people who develop squamous cell carcinoma are more likely to develop more squamous cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Case-Control Studies. Disease Progression. Female. Humans. Male. Middle Aged. Sex Characteristics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468291.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Warshauer E, Warshauer BL: Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy. J Drugs Dermatol; 2008 May;7(5):447-51
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy.
  • The short-term and long-term outcomes of 108 patients with 122 nodular basal cell carcinomas (BCCs), morpheaform BCCs, or low-risk squamous cell carcinomas (SCCs) treated with imiquimod 5% cream at a community-based dermatology practice were retrospectively reviewed.
  • The overall initial tumor clinical cure rate was 93.4% (114/122), with an initial clinical cure rate of 90% (72/80) for BCCs combined, and 100% (42/42) for SCCs combined.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18505136.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


96. Stafanous S: Five-year cycle of basal cell carcinoma management re-audit. Orbit; 2009;28(4):264-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-year cycle of basal cell carcinoma management re-audit.
  • AIM: To complete a 5-year audit cycle for all malignant lid tumours treated by one consultant (Stafanous) and re-audit the first work done in 2000 and 2001/2002.
  • The main aim was to find out the recurrence rate and presence of new lesions in 5-years' follow-up and determine whether it is safe to discharge patients after histological clearance and satisfactory reconstruction outcome rather than 5 years' follow-up.
  • RESULTS: Out of 112 cases identified, 104 were Basal Cell Carcinoma (BCC), 4 Squamous Cell Carcinoma (SCC), 3 Sebaceous Gland Carcinoma (SGC) and 1 Malignant Melanoma (MM).
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Outcome Assessment (Health Care)
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Medical Audit. Melanoma / surgery. Middle Aged. Mohs Surgery. Neoplasm Recurrence, Local. Postoperative Complications. Reconstructive Surgical Procedures. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19839887.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. So PL, Fujimoto MA, Epstein EH Jr: Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. Mol Cancer Ther; 2008 May;7(5):1275-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis.
  • Basal cell carcinoma (BCC) is the most common human cancer.
  • Patients with basal cell nevus syndrome (Gorlin syndrome) are highly susceptible to developing many BCCs as a result of a constitutive inactivating mutation in one allele of PATCHED 1, which encodes a tumor suppressor that is a major inhibitor of Hedgehog signaling.
  • In this study, we assessed whether the effect of tazarotene against BCC carcinogenesis is sustained after its withdrawal and whether tazarotene is effective against preexisting microscopic BCC lesions.
  • In vitro, tazarotene inhibited a murine BCC keratinocyte cell line, ASZ001, suggesting that its effect in vivo is by direct action on the actual tumor cells.
  • Furthermore, inhibition of basal RAR signaling in the skin promoted BCC carcinogenesis, suggesting that endogenous RAR signaling restrains BCC growth.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483315.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109584-06; United States / NCI NIH HHS / CA / U19 CA081888; United States / NCI NIH HHS / CA / CA109584; United States / NCI NIH HHS / CA / CA81888; United States / NCI NIH HHS / CA / R01 CA109584
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Hedgehog Proteins; 0 / Nicotinic Acids; 0 / Receptors, Retinoic Acid; 0 / Retinoids; 81BDR9Y8PS / tazarotene
  • [Other-IDs] NLM/ NIHMS354844; NLM/ PMC4457328
  •  go-up   go-down


98. Son SW, Park SY, Park GM, Ha SH, Lee GW, Lee OS, Hwu Y, Kim AR, Je JH, Oh CH: Ex vivo imaging of basal cell carcinoma using synchrotron phase-contrast X-ray microscopy. Skin Res Technol; 2008 Feb;14(1):13-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex vivo imaging of basal cell carcinoma using synchrotron phase-contrast X-ray microscopy.
  • BACKGROUND/AIMS: There is a need for development of non-invasive methods to improve early diagnosis and screening of suspected malignant lesions.
  • Phase-contrast X-ray microscopy (PCXM) has potential to reveal the structures inside soft tissues, and fine details can be observed without any staining or contrast-enhancing cell preparation.
  • We aimed to investigate the possibility that PCXM can be used to explore the microscopic details of basal cell carcinoma (BCC).
  • METHODS: Paraffin blocks of specimens from patients with basal cell carcinoma were cut with 30 microm thickness for PCXM imaging.
  • [MeSH-major] Neoplasms, Basal Cell / radiography. Skin / radiography. Skin Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18211597.001).
  • [ISSN] 0909-752X
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


99. Mseddi M, Dammak A, Jellouli M, Ghorbel S, Bouassida S, Marrekchi S, Zahaf A, Turki H: [Profile of basal cell carcinomas of the scalp after radiotherapy for tinea capitis (about 63 cases)]. Rev Med Liege; 2006 Oct;61(10):724-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Profile of basal cell carcinomas of the scalp after radiotherapy for tinea capitis (about 63 cases)].
  • [Transliterated title] Profil des carcinomes basocellulaires du cuir chevelu secondaires a une radiothérapie pour teigne (a propos de 63 cas).
  • The induction of basal cell carcinoma (BCC) of the scalp by X-ray therapy for tinea capitis is well known.
  • The aim of the study was to specify the epidemiological, clinical and histological characteristics of this disease.
  • It represents the most frequent tumour developing on irradiated scalp.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Head and Neck Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Scalp. Skin Neoplasms / etiology. Tinea Capitis / radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17209506.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


100. Boswell JS, Flam MS, Tashjian DN, Tschang TP: Basal cell carcinoma metastatic to cervical lymph nodes and lungs. Dermatol Online J; 2006;12(6):9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma metastatic to cervical lymph nodes and lungs.
  • Metastatic basal cell carcinoma (MBCC) of the skin is rare in occurrence and may initially elude proper diagnosis and management.
  • In addition to the more commonly metastasizing carcinomas, metastases from a cutaneous basal cell carcinoma primary tumor should be considered when evaluating cervical lymph node metastases of an uncertain head and neck primary.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Carcinoma, Papillary / diagnosis. Diagnostic Errors. Head and Neck Neoplasms / diagnosis. Lung Neoplasms / secondary. Lymphatic Metastasis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Male. Middle Aged. Neck Dissection. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Second Primary. Radiotherapy. Seminoma. Skin Neoplasms / surgery. Taxoids / administration & dosage. Testicular Neoplasms. Thyroidectomy. Unnecessary Procedures

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083889.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down






Advertisement